Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

MMPs in learning and memory and neuropsychiatric disorders

Anna Beroun, Shiladitya Mitra, Piotr Michaluk and 3 more (opens in a new tab)

Cellular and Molecular Life Sciences · 2019 · Review · CC BY

doi:10.1007/s00018-019-03180-8 (opens in a new tab)

Abstract

Matrix metalloproteinases (MMPs) are a group of over twenty proteases, operating chiefly extracellularly to cleave components of the extracellular matrix, cell adhesion molecules as well as cytokines and growth factors. By virtue of their expression and activity patterns in animal models and clinical investigations, as well as functional studies with gene knockouts and enzyme inhibitors, MMPs have been demonstrated to play a paramount role in many physiological and pathological processes in the brain. In particular, they have been shown to influence learning and memory processes, as well as major neuropsychiatric disorders such as schizophrenia, various kinds of addiction, epilepsy, fragile X syndrome, and depression. A possible link connecting all those conditions is either physiological or aberrant synaptic plasticity where some MMPs, e.g., MMP-9, have been demonstrated to contribute to the structural and functional reorganization of excitatory synapses that are located on dendritic spines. Another common theme linking the aforementioned pathological conditions is neuroinflammation and MMPs have also been shown to be important mediators of immune responses.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction to MMPs in the brain

Extracellular matrix (ECM) in the brain has emerged as an important reservoir of signaling molecules, which can influence synaptic plasticity, synaptogenesis, neurite outgrowth and other processes occurring in central nervous system. Many suggest now that “tetrapartite synapse” is a functional unit of the brain, where ECM plays equally important roles to pre-, post-synaptic terminals and glial cells’ invaginations. Matrix metalloproteinases (MMPs) are among the major modulators of ECM, providing precise proteolysis of its components, in addition to performing limited cleavage of cell adhesion molecules (CAMs), neurotrophins and cytokines. MMPs make up a family of over 20 proteins in humans and rodents (predominantly secreted, but six are membrane-bound), each encoded by a different gene. MMPs are a part of bigger, metzincin group of proteases, which all have Zn2+ and the conserved methionine residue in their active site.

Based on their domain structure, MMPs are subdivided into eight groups, but all are composed of (starting from N-terminus): a signal peptide, propeptide, catalytic domain and in most cases hinge region and hemopexin domain. The signal peptide is removed after the protein enters the endoplasmic reticulum. MMPs are expressed as inactive zymogens, where the propeptide has conserved cysteine residue binding Zn2+ in the active center of the enzyme. Activation occurs when the interaction between cysteine and Zn2+ is disrupted, which can be achieved by cleaving the propeptide off (by other proteases), as well as by other means, such as S-nitrosylation, detergents or sulphates. The catalytic domain of all MMPs has a highly conserved Zn2+ binding motif—HExGHxxGxxH (where x is any amino acid) and a distinct β-turn (usually ALMYP). That is why all MMPs have distinguishable, but often overlapping, substrate specificities. Moreover, the catalytic domain of MMPs requires binding of Ca2+ ions which are required for the stabilization of its active state. Gelatinases (MMP-2 and -9) have additional fibronectin type II inserts, which are required for collagen and elastin binding and cleavage.

Most of MMPs (except of MMP-7, MMP-26 and MMP-23) have hinge region and hemopexin domain, which is responsible for interaction with substrates, dimerization and binding of one of four endogenous tissue inhibitors of metalloproteinases (TIMPs). MMP-23 instead of hemopexin domain has unique cysteine-rich, proline-rich and IL-1 type II receptor-like domains. MMP-14, MMP-15, MMP-16, and MMP-24 have also a transmembrane domain which anchors them to the cell membrane whereas MMP-17, and MMP-25 have on their C-terminus a glycophosphatidyl inositol membrane anchoring signal.

Since excessive activity of MMPs might be detrimental to the tissue (as it happens under some pathological conditions), the enzyme gene expression, mRNA maturation, distribution and survival, as well as protein release and activation are all strictly regulated. This can be best described in the example of one of the most studied MMP, MMP-9. MMP-9 transcription is activity regulated by inducible transcription factors, such as AP-1, then MMP-9 mRNA transport, survival and translation are also activity regulated, as it has been demonstrated for neurons. MMP-9 is present within cells in vesicles distributed along microtubules and microfilaments and is secreted in a Golgi-dependent pathway in 160–200 nm vesicles. Notably, MMP-9 is often found in the same secretory vesicles as its inhibitor, TIMP-1 and although secreted upon stimulation, it is thought to act very focally and can be concentrated at the cell membrane by binding to cell adhesion molecules such as the hyaluronian receptor CD44 or integrins.

The activation of proMMP-9 occurs extracellularly after its release and is controlled by a cascade of steps involving other proteases, inhibitors and receptors. For example, serine proteases: tissue plasminogen activator (tPA) or urokinase plasminogen activator (uPA), which can be docked to the membrane by its receptor, uPAR, activate the conversion of plasminogen to plasmin, which in turn can activate proMMP-9. Additionally, some MMPs such as MMP-11 or MMP-28 and all membrane-type MMPs (MT-MMPs) have also a furin-like recognition motif in their propeptide and can be thus activated inside the cell before secretion or exposure to cell surface, and activate other secreted MMPs. Once activated, MMP-9 can be inhibited, particularly by TIMP-1, but also by other TIMPs. This is because, similarly to redundancy in MMPs substrate specificity, there is a significant overlap in the affinity of TIMPs to different MMPs.

TIMP-1 can inhibit MMPs directly by binding through its N-terminal domain to the catalytic site of the enzyme. Interestingly, inhibition of MMP-9 can be also achieved by binding TIMP-1 C-terminus to the hemopexin domain of MMP-9, thus blocking its interaction with substrate or membrane docking proteins. MMP-9 and TIMP-1 share the same release kinetics and it has been shown that those two proteins can be co-released even from a single vesicle. Moreover, it has been proposed by Ogata and co-workers that TIMP-1 bound to MMP-9 via the hemopexin domain is also important during activation of the gelatinase by other MMPs, like MMP-3. Finally, activated MMP-9 binds through its hemopexin domain to low-density lipoprotein receptor-related protein, which is an endocytic receptor for this and many other proteins, and after endocytosis leads to the destruction of MMP-9.

All the regulatory mechanisms, such as secretion, interaction with membrane receptors, internalization and TIMP-dependent inhibition, are to limit spatially and temporarily MMP’s activity outside the cell and prevent excessive, potentially pathological activity. An interesting example of physiological, tight control by TIMP-1 over MMP-9 has been recently published by Magnowska et al., where both proteolytic activity of MMP-9 and its following inhibition by TIMP-1 were discovered to be necessary for synaptic plasticity (see below). Interestingly, activation of MMP-9 in the brain tissue can be achieved by the degradation of TIMP-1 by cathepsin B, a lysosomal enzyme, which upon stimulation can be released to extracellular space and activate MMP-9. Another example of MMP activating cascade is that of MMP-2, as it requires the formation of tertiary complex with TIMP-2 and MT1-MMP. TIMP-2 forms a link between dimerized MT1-MMP and the hemopexin domain of pro-MMP-2. This leads to cleavage of MMP-2 propeptide by MT1-MMP and thus its activation.

As already mentioned, MMPs are inhibited by four endogenous inhibitors, TIMP-1 to TIMP-4. They are all soluble and share a common structure, but their role is very diverse. For example, TIMP-1 can act independently to its inhibitory activity as a growth factor suppressor or a cytokine. The cytokine effect of TIMP-1, which results in inhibition of neurite outgrowth and increase in growth cone volume, is mediated through its internalization by LRP-1.

Expression in the brain

Among the MMPs, many have been shown to be expressed in the brain, namely: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 and MMP-28. Notably, a number of those are expressed in the brain only under very particular physiological and/or pathological circumstances.

MMP-1 (collagenase 1) expression in the brain has often remained undetected. However, recent studies have shown MMP-1 immunoreactivity in the olfactory lobe, entorhinal cortex, pontine nuclei, and periaqueductal gray, but not in the hippocampus. Moreover, MMP-1 protein level was increased at 4 h following systemic kainate administration or after ischemic stroke, and was shown to be present in the brains of Alzheimer’s disease patients. MMP-1 seems to be mostly expressed by glia, but there are also reports indicating its presence in neurons. MMP-1 was also shown to enhance proliferation and increased differentiation towards neurons of hippocampal neural progenitor cells. Moreover, MMP-1 overexpression in transgenic mice under GFAP gene promoter enhances dendritic complexity and causes deficits in learning and memory. Literature suggests that MMP-1 in the brain acts mainly through activating protease activated receptor 1 (PAR1), and thus increasing cytoplasmic Ca2+ concentration, as it was proven also in platelets. Interestingly, PAR1 was shown to be cleaved and activated by another collagenase which is also expressed in the brain, MMP-13, however, this relationship was studied in cardiac fibroblasts and cardiomyocytes.

MMP-2 (gelatinase A) is one of the two gelatinases most extensively studied in the brain. It is constitutively expressed mainly by astrocytes, however, many studies find it to be localized also in some cortical, and cerebellar neurons, as well as in the hippocampus and nucleus accumbens (NAc). MMP-2, like most of the MMPs in the brain, is expressed at much higher level during early postnatal development than during adulthood, reaching peak around day 4 after birth. MMP-2 expression can be induced under various pathological conditions (see below). In particular, reactive astrocytes show increased expression of MMP-2. MMP-2 in astrocytes is localized at the leading edge of processes, where it regulates actin cytoskeleton and thus affects cell migration.

MMP-3 (stromelysin 1) is, as many other MMPs, expressed during development in the central nervous system. Around embryonic day 15, it is expressed in most brain areas in rat, and in mouse it is found in neurons of the ventricular zone. In late prenatal period, MMP-3 is also expressed in mature oligodendrocytes. Until postnatal day 10, MMP-3 is expressed by most cells of the cerebellar cortex, striatum and hippocampus and can be found in both neuronal and glial cells. MMP-3 is also expressed during postnatal brain development in cerebellum, specifically in Purkinje cell somata and dendrites as well as in some granule cells. In the adult brain, MMP-3 expression level is either very low or negligible, but some studies report its expression in the hippocampus, especially during learning paradigms. A recent study of Wiera et al. shows that in the stratum radiatum of hippocampus, MMP-3 seems to be mainly expressed by astrocytes in a sparse punctate manner. MMP-3 has a very broad range of substrates in the brain. It was shown, for example, to cleave almost all components of perineuronal nets. MMP-3 is upregulated in many brain pathologies, disrupting blood–brain barrier, causing neuroinflammation and apoptosis. In such conditions, it is expressed by injured neurons, oligodendrocytes, astrocytes and reactive microglia or invading macrophages. Induction of MMP-3 expression depends on binding of NFκB to its gene promoter upon the release of inflammatory mediators, e.g., interleukin-1β caused by ischemia, traumatic brain injury (TBI) or infections. In addition, MMP-3 acts itself as a signaling molecule and creates positive feedback for inflammatory response, as it causes activation of microglia and synthesis of cytokines, e.g., tumor necrosis factor-α, interleukin-1β, or interleukin-6. However MMP-3 was also shown to have beneficial effects during pathological states as it can cleave Fas ligand, can promote synaptogenesis and is involved in remyelination.

MMP-7 (matrilysin) expression during development, as well as in the normal adult brain, is often described as negligible. Most reports that detect MMP-7 in normal brain conditions point to glia (most often microglia) as MMP-7 expressing cells; although the issue of MMP-7 source in the brain has often not been addressed in various studies. Interestingly, Le and Friedman reported a high level of MMP-7 in hippocampal neurons, which dropped after seizures induced with kainic acid. MMP-7 is, though, strongly upregulated during such pathological conditions in the brain as multiple sclerosis, experimental autoimmune encephalomyelitis, HIV dementia or brain tumors. Among the substrates of MMP-7 in the brain, the most prominent are pro-nerve growth factor (pro-NGF), SNAP-25, the NR1 subunit of NMDA receptor or myelin-associated glycoprotein.

MMP-9 (gelatinase B) is the most studied MMP in the brain, with its expression in naïve brain kept on a very low level. It is found in hippocampus, cerebellum and cerebral cortex and is predominantly expressed by neurons, but also by glia. MMP-9 expression is tightly regulated on different levels (see above) and it peaks during early development. Even though MMP-9 levels in the adult brain are low, they are upregulated during neuronal increased activity/plasticity but also, as so many other MMPs in pathological situations (see below and for recent reviews:). Most interestingly, MMP-9 activity, as well as its mRNA are present in the vicinity of synapses.

MMP-14 (MT1-MMP) is most often studied in the brain in the context of gliomas, where it is highly expressed along other MMPs. Under pathological and inflammatory conditions, it has been found expressed by microglia. MT1-MMP is, however, expressed on a low level in the normal adult brain. MT1-MMP in the hippocampus is predominantly localized in neuronal cell layer and expression of MT1-MMP is elevated upon BDNF treatment in mixed neuronal cultures. In retina, it is expressed in retinal ganglion cells as well as in Müller glia. Interestingly, MT1-MMP expression increases in female hippocampus upon the presentation of novel odor.

MMP-24 (MT5-MMP) is expressed at relatively high levels in the adult brain, particularly in the cerebellum, but also hippocampus and olfactory bulb. It can be found predominantly in neurons and its expression is increased during development regulating axonal growth and dendritic tree formation of Purkinje cells.

Synaptic plasticity, learning and memory: MMPs expression and function

Brain plasticity refers to the capacity for structural and functional reorganization of the neural networks in response to external challenges. Beside learning and memory, which allow for adaptation to the changing environment, neuroplasticity is necessary to recover after disorders and injuries. Brain plasticity is manifested at many levels in the nervous system, ranging from molecular events, such as changes in gene expression, protein availability and function, to cellular physiology, to behavior. At the cellular level, the plasticity is supported by dynamic modifications in neural connectivity and excitability that are driven by molecular changes in synapses, entire neurons and glial cells.

Synapses are particularly prone to dynamic alterations, and thus believed to play a major role in the plasticity. Aberrant synaptic plasticity leads to many pathological conditions, e.g., epileptogenesis, drug addiction, autism spectrum disorders, schizophrenia or depression. Compensatory brain plasticity may reduce the detrimental effects of such pathologies as multiple sclerosis, Parkinson’s disease, cognitive deterioration or Alzheimer’s disease. Induction and maintenance of activity-dependent synaptic plasticity adaptations require a temporal and spatial control of a complex sequence of events that result in the modification of pre- and postsynaptic content, as well as remodeling of the entire tetra-synapse morphology.

Excitatory synapses that are particularly plastic, are predominantly located on small dendritic protrusions called spines, whose morphology can be taken as a proxy for the synaptic efficacy. Small dendritic spines often harbor silent synapses, equipped with a limited number of NMDA receptors for glutamate and virtually missing AMPA receptors (AMPAR) for this excitatory neurotransmitter. Increased synaptic efficacy that may produce neuronal depolarization associates with the accumulation of AMPAR (and thus enhanced glutamate responsiveness) that in turn correlates with increased spine volume and enlargement of the dendritic spine head, producing spines with a mushroom shape.

MMPs have repeatedly been implicated in synaptic plasticity thanks to their capacity to act in a tightly controlled, short temporal window, targeting extracellular matrix, cell adhesion molecules, synaptic receptors, neurotrophins and other proteins implicated in synaptic efficacy and remodeling. Studies with broad spectrum MMPs inhibitors have demonstrated impairments in various short- and long-term plasticity models including paired pulse and theta burst facilitation, maintenance of long-term potentiation (LTP), induction and magnitude of long-term depression (LTD) in the hippocampus, as well as ocular dominance plasticity in the visual cortex and barrel cortex plasticity, resulting from sensory deprivation.

Recent studies have shed light on the role of MMPs in synaptic plasticity. In this regard, the best studied involvement of metalloproteinase function in synaptic plasticity processes concerns the activity of MMP-9. This issue has been covered by extensive reviews, so it will be only briefly presented here.

MMP-9 is released from the postsynaptic compartment of excitatory synapses in an activity-dependent manner. Upon activation, MMP-9 cleaves (among others) such synaptic cell-adhesion molecules as: β-dystroglycan, neuroligin-1, nectin-3, intercellular adhesion molecule-5 (ICAM-5), synaptic cell adhesion molecule-2 and collapsin response mediator protein-2, affecting NMDA receptors mobility and function at the synapse. Chemical LTP experiments on dissociated and organotypic hippocampal cultures revealed MMP-9-dependent spine enlargement, accumulation of AMPA receptors in the synapse and increase in the spike count and bursts frequency. Transient function of MMP-9 is a requirement for maintenance of the late phase, NMDA-dependent LTP at various pathways in the hippocampus, prefrontal cortex (PFC), as well as basal and central nuclei of the amygdalar complex. Furthermore, Dziembowska et al. reported increases in MMP-9 mRNA levels in the hippocampal dentate gyrus of rats with LTP evoked therein by the perforant path stimulation.

The increase of limited MMP-9 activity at the synapse has a profound impact on synaptic morphology. It was reported that activation of this metalloproteinase during LTP induction leads to the enlargement of dendritic spines. This, actually, is a two-step process that begins with the MMP-9-mediated elongation of dendritic spines into apparently more immature, filopodium-like shape. Then, only upon inhibition of the proteolytic activity, which in neurons might be mediated via specific inhibitor TIMP-1, dendritic spines assume larger, mushroom-like shape.

As far as learning and memory are concerned, MMP-9 activity was reported to be increased after Morris water maze, head-shake response, passive avoidance and appetitive learning. Importantly, in addition to the functional role of MMP-9 in activity-dependent synaptic remodeling, blocking the enzyme has dramatic consequences on learning processes in vivo. Using either pharmacological inhibition or genetic ablation, it was demonstrated that MMP-9 activity was necessary for hippocampus-dependent learning, as shown in Morris water maze, contextual fear conditioning and reconsolidation of fear memory, as well as amygdala-dependent positive reinforcement conditioning in sucrose preference task. On the other hand, fear conditioning to an auditory cue, as well as avoidance learning of an exposure to an air-puff or a bitter taste in the Intellicages, remained undisturbed in MMP-9 KO mice. Of note, LTP to lateral nucleus of the amygdala is believed to support the aversive learning, such as aforementioned fear conditioning to an auditory cue. Therefore, lack of MMP-9 requirement in the aversive learning might be explained by the fact that the enzyme is not obligatory for the lateral amygdala synaptic plasticity and LTP.

Interestingly, MMP-9 has also been considered as a player in human cognition. In the study of Bach et al., blocking the activity of MMP-9 by administration of its inhibitor doxycycline 3.5 h prior to the fear conditioning procedure, reduced the fear response in human subjects measured 1 week after the test. This might suggest that lower MMP-9 activity during fear acquisition phase attenuated the formation of the fear memory. Moreover, reduced mRNA and protein levels of MMP-2, MMP-9 and TIMP-2 were observed in patients diagnosed with depression and displaying lower performance in cognitive tasks, as compared to healthy subjects. Furthermore, within the healthy control group, there was a positive correlation between MMP-2 (protein level), MMP-9 and TIMP-2 (mRNA levels) and performance in cognitive tasks: visuospatial performance, working memory tasks, auditory-verbal memory, the effectiveness of learning processes and verbal fluency. Similar positive correlation between MMP-9 serum level and decision-making abilities was observed in bulimia nervosa patients. Another report on MMP-9 involvement in cognition comes from a study on male bipolar patients. Those subjects carrying a MMP9 gene polymorphism −1562C/C, apparently characterized with lower promoter activity, performed better in cognitive tests than people with other genotypes. It should be, however, noted that recent study by Gregory et al. has questioned the role of this gene polymorphism in regulating MMP-9 expression in the brain and, furthermore, has demonstrated the gene polymorphism affects the brain structure and function that obviously may contribute to cognition.

MMP-3 role in learning and memory is best described in hippocampus-dependent learning tasks. In a spatial memory test—the Morris water maze—it was reported that MMP-3 mRNA and protein levels were elevated during the acquisition phase, while pharmacological inhibition of MMP-3 activity disrupted this learning process. The increase of MMP-3 level in this spatial learning task was prevented by the blocking of the NMDA receptor with the MK-801 antagonist. Similarly to spatial learning, a passive avoidance test revealed an increase of MMP-3 protein level in the hippocampus within a few hours post training, suggesting the role of MMP-3-induced ECM remodeling in associative memory consolidation. Habituation increases MMP-3 expression in hippocampus and PFC, while injection of MMP-3 inhibitor into the hippocampus interferes with this task.

Looking closer into cellular mechanisms of MMP-3 action in the hippocampus, it was reported that, similarly to MMP-9, a transient activation of MMP-3 (within 30 min window post stimulation) is necessary for synaptic potentiation, described in the excitatory postsynaptic potential (EPSP)-to-spike potentiation phenomenon—a long-term potentiation of synaptic inputs. EPSP-to-spike potentiation is a NMDA receptor-dependent process and the timing of MMP-3 activation overlaps with the short window of NMDARs activity requirement to prolong the potentiation. MMP-3 has been shown to cleave NR1 subunit of NMDA receptors in in vitro neuronal cultures, therefore, it could affect synaptic NMDARs function, necessary during plastic adaptations. Moreover, MMP-3 can affect synaptic efficacy by mediating the structural plasticity of dendritic spines. As reported in the visual cortex of MMP-3 KO mice, the morphology of dendritic spines was impaired, namely, the higher number of short, mature spines perturbed open-eye potentiation in visual cortex of these knockout mice.

Similarly to MMP-3, MMP-7 has also been shown to affect spine morphology in a NMDAR-dependent manner. In cultured hippocampal neurons, application of recombinant MMP-7 induced a robust reorganization of spines, changing mushroom-shaped spines into filopodial type. This effect was triggered by rapid F-actin reorganization (observed after 10–20 min) and was dependent on NMDAR function (blocked by MK-801). In fact, in acute cortical slices, MMP-7 cleaved NR1 and NR2A subunits of NMDARs. This caused a reduction in NMDA-induced Ca2+ influx. Therefore, MMP-7 may directly affect NMDARs function and its downstream signaling, pivotal for synaptic plasticity. Moreover, in the presynaptic terminus, application of recombinant MMP-7 on cultured hippocampal neurons decreased the readily releasable pool of synaptic vesicles, decreased the size of active zones and inhibited vesicle recycling. MMP-7 effects on vesicle recycling could be partially explained by its cleavage of the SAP-25 protein (synaptosomal-associated protein of 25 kDa), which disrupts the vesicle docking complex.

Among MT-MMPs involved in synaptic functions in the brain, MT5-MMP (MMP-24) is the best characterized. In comparison to other MMPs, it is highly expressed in the brain and it is present at the synapses thanks to binding to AMPA receptor binding protein (ABP), and glutamate receptor interacting protein (GRIP). Monea and co-workers have also identified N-cadherins as MT5-MMP substrates, which further implies the important function of this MMP at the synapse. Additionally, MT5-MMP is capable of cleaving β-amyloid precursor protein (APP) creating carboxy-terminal fragments of APP, which are able to impair hippocampal LTP as well as reduce neuronal activity in vivo. In a study of traumatic brain injury (TBI) MT5-MMP protein level was increased during synaptic remodeling after the injury and blocking MMPs activity restored levels of N-cadherin and partially restored LTP induction. In those experiments MT5-MMP was, however, expressed mainly in reactive astrocytes and applications of GM 6001, a broad spectrum MMP inhibitor, could not exclude the involvement of other MMPs in this process.

MMPs in epilepsy and epileptogenesis

Epilepsy is a brain disorder characterized by an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological and social consequences of this condition. It is also manifested in the structural changes observed in epileptic brain, such as neuronal reorganization, especially prominent within hippocampus, including axonal sprouting.

In fact, epilepsy is not a homogenous disorder, but rather a collection of subtypes with a variety of etiologies. Thus, epilepsies are divided based on the underlying etiology into: (1) genetic, which are caused by genetic factors; (2) structural/metabolic, which have distinct structural or metabolic conditions, including acquired epilepsies caused by stroke or brain trauma; and, (3) of unknown cause. Acquired epilepsies constitute about 30% of all cases of epilepsy and are most commonly caused by stroke, brain trauma, alcohol use, neurodegenerative diseases, or infection. In acquired epilepsies, brain-damaging insult leads to epileptogenesis (latency period without seizure) lasting up to several years that culminates in the appearance of seizures and epilepsy diagnosis.

Among epilepsy types with not well-defined genetic causes, particularly common are temporal lobe epilepsy (TLE) and post-traumatic epilepsy (PTE). TLE is the most frequent and drug-resistant type of adult focal epilepsy, characterized by the appearance of epileptic foci in such temporal lobe structures as hippocampus or amygdala. PTE develops often as a result of TBI caused by an external mechanical force. This initial brain insult triggers a cascade of events called epileptogenesis that can last in humans for years and that finally leads to the appearance of spontaneous recurring seizures (epilepsy).

There are several mechanisms by which MMPs may participate in epileptogenesis and epilepsy, including blood–brain barrier breakdown, and contributions to inflammatory reactions and synaptic plasticity. The best examined proteinase with a significant role in different models and types of epilepsy appears to be MMP-9.

Zhang et al. were the first to report that MMP-9 level (as well as MMP-2) increased in a brain region- and age-related manner in rats subjected to proconvulsive treatment with kainic acid (KA)—a well-recognized model of TLE. Similar increases were also observed after treatment with bicuculline (GABAA receptor antagonist, provoking seizures). Next, Szklarczyk et al. demonstrated that MMP-9 expression—at the levels of mRNA, protein and enzymatic activity—was markedly upregulated by KA. Of particular interest was surprising finding that those responses were limited to the dentate gyrus, i.e., the hippocampal region undergoing the most extensive post-KA plasticity, presumably supporting epileptogenesis. Then, Wilczynski et al. directly investigated the role of MMP-9 in two animal models of epileptogenesis, namely, KA-evoked status epilepticus (SE, a condition known to provoke the development of epilepsy) and proconvulsive pentylenetetrazole (PTZ, a GABAA receptor antagonist) chemical kindling. They showed that the sensitivity to PTZ kindling was decreased in MMP-9 knockout mice but was increased in transgenic rats with neuronal overexpression of MMP-9. Furthermore, Wilczynski et al. demonstrated that MMP-9 deficiency diminished KA-evoked pruning of dendritic spines and decreased aberrant synaptogenesis after mossy fiber sprouting. Finally, they also reported that MMP-9 was associated with excitatory synapses, where both MMP-9 protein levels and enzymatic activity become strongly increased upon seizures. Subsequently, the presumed role of MMP-9 in epileptogenesis was confirmed by Mizoguchi et al., who showed enhanced MMP-9 activity and expression in the injured hippocampus in PTZ kindling model. The role of MMP-9 in the development of epilepsy has been also supported by studies with such models of epilepsy as treatment with either pilocarpine or 4-aminopyridine (seizure-inducing drugs), as well as the use of Wistar Albino Glaxo Rijswijk (WAG/Rij) rats that display higher propensity for seizure activity.

PTE is a life-long complication of TBI, where seizures are provoked by head injury. Little is known about the mechanisms that lead to post-injury epilepsy development. Based on data from experimental models and human tissue, epilepsy resulting from head injury is associated with various morphological and physiological changes, such as neurodegeneration, myelin and axonal injury, axonal and synaptic plasticity, changes in spine density/morphology, neurogenesis, gliosis, blood–brain-barrier damage, angiogenesis, changes in extracellular matrix and molecular reorganization of ion channels in individual neurons.

It has been reported that in fluid percussion injury (FPI) and controlled cortical impact (CCI) models of TBI, tissue level of mRNA and active form of MMP-9 protein, were increased in ipsilateral cortex and hippocampus after injury. This increase was observed during the first-week post-injury. Besides the upregulation of MMP-9, time-dependent increase of its inhibitor, TIMP-1 mRNA has been observed in ipsilateral cortical areas. Unbalance between MMP-9 and TIMP-1 as a result of insult, could induce various structural, cellular and neurochemical changes, such as mossy fiber sprouting, synaptogenesis, changes in expression of β-dystroglycan, BDNF, integrins as well as cell death or neurogenesis. These processes could lead to increased excitability and changes in neuronal circuitry. The possible role of MMP-9 in post-TBI consequences was confirmed by finding that MMP-9 KO mice displayed less prominent motor deficits and significantly smaller post-TBI lesion volumes than wild-type siblings. Recently, Pijet et al. have demonstrated that PTE occurrence is correlated with the size of the lesion upon injury, where the high level of MMP-9 characterized by a large lesion area, predisposes to PTE development, while inhibition of MMP-9, with small lesion volume, protects from PTE. Pijet et al. have also shown that MMP-9 deficiency decreased the seizure appearance in a PTE model, whereas overexpression of MMP-9 increased the likelihood of spontaneous seizures.

The contribution of MMP-9 to epileptogenesis has further been substantiated by the use of MMP-9 inhibitors. It has been shown that inhibitors of MMP-9 used in status epilepticus animal model, reduced neuronal cell death, modified the inflammatory response by suppression of pro-inflammatory cytokines in microglial cells. Finally, inhibition of dendritic spines morphological reorganization and severity of seizures induced in kindling model has been observed by Yeghiazaryan et al., who proved the supposition that pharmacological inhibition of MMPs might be beneficial by suppressing seizure progression in animal models of epilepsy.

In addition, in humans with different types of epilepsy, the occurrence of the seizures is correlated with the elevated levels of MMP-9 in serum or plasma as well as in the cerebrospinal fluid. Similarly, the ratio of MMP-9 to TIMP-1 was increased under epileptic conditions. It has been speculated that this phenomenon can promote brain blood barrier damage, which is correlated with elevated expression of MMP-9 in serum. Moreover, studies made on brain surgery tissue revealed increase in MMP-9 level in epileptogenic lesions associated with epileptic conditions such as focal cortical dysplasia (FCD), tuberous sclerosis or TLE. Interestingly, in children with intractable and non-intractable epilepsy, salivary MMP-9 concentration was decreased compared to controls. Zybura-Broda et al. have investigated epigenetic changes on the MMP9 gene promoter, finding an increased DNA demethylation in human epileptic tissue as compared to control brain tissue. Notably, the authors have also demonstrated that progressive Mmp9 gene promoter demethylation accompanied the development of seizure susceptibility in PTZ kindled rats.

The role of other MMPs in epilepsy development appears poorly investigated. An expression of MMP-2 in epileptogenesis process has often been examined simultaneously with MMP-9. Delayed increase in MMP-2 activity was observed in animal models of TLE after systemic injection of pilocarpine or kainic acid. The increase of MMP-2 was less pronounced compared to MMP-9, nevertheless being significant. However, as so far, there is no further data describing the involvement of MMP-2 in epilepsy development. MMP-2 may increase the permeability of the blood–brain barrier which encourage seizures appearance and facilitates epilepsy development. Interestingly, MMP-2 serum levels in patients with epilepsy were significantly lower.

In the kainic acid model of TLE, MMP-3 expression was found to be increased. Moreover, in response to TBI, both hippocampal and CSF levels of MMP-3 were elevated. In contrast, serum MMP-3 levels in epileptic patients was found to be decreased. Elevated expression of hippocampal MMP-3 mRNA and protein after TBI as well as SE was also reported. Gorter et al. also demonstrated an enhancement in the expression of MMP-2 and MMP-14 induced by SE evoked by electrical stimulation of the hippocampus.

Using an unbiased approach of antibody microarrays, Konopka et al. found an elevated expression of MMP-1, -2, -8, -10, and -13, in addition to MMP-9, in the epileptic brain tissue from patients with FCD. However, the expression of these proteinases was not as pronounced and/or not as consistent among patients as the expression of MMP-9. Among these other MMPs, especially striking was the upregulation of MMP-2 in adult patients only, but the significance of this finding is presently unclear.

MMPs in mental disorders: focus on autism spectrum disorders, fragile X syndrome, schizophrenia, bipolar disorder, chronic stress and major depression

Mental health is as a state of well-being that enables individuals to realize their abilities, deal with the normal stresses of life and work productively. Mental health disorders appear when the homeostasis is lost and abnormalities in thoughts, perceptions, emotions, behavior and relationships with others appear. The rise in number of people suffering from mental disorders makes them a topic of considerable and growing research interest. Importantly, the neuropsychiatric disorders often share comorbidities, hence it may seem difficult to draw a hard line between particular medical conditions. Therefore, it is legitimate to consider that for this reason they also share some aspects of underlying, including molecular, mechanisms. For the purpose of the present review, we shall focus on stress, major depression, bipolar disorder, autism spectrum and schizophrenia– the most common neuropsychiatric disorders. These diseases pose particular research challenges, as they are all difficult to model in experimental animals. In fact, the animal studies usually focus on reproducing and investigating only selective disease symptoms. Fortunately, the very intense effort on human genomics and proteomics has resulted in revealing major categories of possible molecular players underlying the neuropsychiatric conditions. Those categories are often overlapping among those conditions, with the major ones being: inflammatory/immune responses, epigenetics and gene regulation, and finally synaptic plasticity. Considering the fact that MMPs may fall into both inflammatory/immune category and synaptic plasticity and, as it has been well documented for MMP-9 in the brain, may be under very tight, including epigenetic, gene regulation (see above), there is no surprise that MMPs have been implicated, especially MMP-9, by virtue of gene associations and/or protein levels, in neuropsychiatric disorders.

MMPs in stress and depression

Evolutionarily, stress is a response of the organism to a challenge or threat. When working properly in normal life it helps to maintain balance, and in an emergency situation, to survive. A chronic stress, however, is like a continuous emergency mode that can rewire the brain, so it becomes more vulnerable to anxiety or even a major depression (MD) and other health problems.

Human data

MMP9 −1562 C/T (C1562T) gene promoter polymorphism is considered as functional, since a C to T substitution results apparently in a loss of binding of a nuclear silencer protein to this region of the MMP9 gene to produce an increase in transcriptional activity. This polymorphism has been found to be associated with depression, with the C/C genotype or C allele increasing the risk of susceptibility to middle age depression and the T allele, on the other, hand reducing the risk. The same study also found that in subjects bearing another MMP9 gene polymorphism of unknown functionality, namely, −1702 T/A, the T/T genotype or T allele led to increase in risk of recurring depressive disorder, whereas the A/A allele led to lower risks. As far as other MMPs are concerned, analysis of MMP7 −181 A/G gene polymorphism revealed its strong association with higher incidence of recurring depressive disorder. This research also pointed that dual occurrence of C/T C-735T/MMP2/genotype and G/G A-181G/MMP7/genotype, and, C/T–T/T genotypes of the MMP2C-735T and MMP9T-1702A polymorphisms, were also associated with increased risks of recurrent depression.

Expression analysis of MMPs revealed that MMP-9 was upregulated in serum upon two stressful stimuli (recall of either an event that frustrated the patient or a mental arithmetic task) in patients with coronary disease. In another study, an increased level of MMP-9 was found in the blood of patients with major depression. MMP-9 levels were also correlated with the severity of depression and the quality of life of the patients. MMP-9 levels were also found associated with several psychological factors linked with depression in a middle-aged population. Another interesting observation was that in patients receiving electro convulsive therapy (ECT) as a treatment for depression, the serum levels of MMP-9 decreased significantly in those patients who did not show relapse of depression. Interestingly, transcript and protein levels of MMP-2, MMP-9 and TIMP-2 were found to be downregulated in patients with the recurrent depressive disorder as compared to healthy individuals. Finally, both mRNA and protein levels of several MMPs (MMP2, MMP-7 and MMP-9) were demonstrated to be higher in patients with MD, when compared to healthy controls.

Animal experiments

In an animal model of prolonged stress (restrain of a mouse for 6 h per day, repeated for 21 days) that may contribute to depression, proteolytic activity of MMP-9 was shown to be enhanced in CA1 but not in CA3 of the hippocampus. This result correlated with impaired social interactions that were reinstated following infusion of MMP inhibitor into the hippocampus. Furthermore, Aguayo et al. have found that a single stress exposure (2.5 or 24 h restrain) increases MMP-9 levels and activity in the hippocampus.

MMPs in autism spectrum disorders and fragile X syndrome

Autism spectrum disorders (ASD) are considered to be neurodevelopmental disorders that affect communication and behavior. They are classified as a “spectrum” as there is varied range of manifestation of the phenotype.

Human data

Probably the most extensively studied genetic alteration linked to ASD concerns FMR1, encoding fragile X mental retardation protein (FMRP). Missing FMRP produces fragile X syndrome (FXS). Most interestingly, MMP-9 was found to be upregulated in the serum of patients with FXS, and, moreover, minocycline treatment that decreased MMP-9 levels led to clinical improvements in the patients. In parallel, Janusz et al. have demonstrated that FMRP controls local, dendritic/synaptic translation of MMP-9 and then Gkogkas et al. using post mortem brains from FXS patients showed that phosphorylation of the mRNA 5′ cap binding protein, eukaryotic initiation factor 4E (eIF4E), was elevated concomitantly with increased expression of MMP-9 protein. More generally, the analysis of amniotic fluid in patients with ASD showed elevated levels of MMP-9. Increased MMP-9 was also found in postmortem cortex of ASD patients.

Animal experiments

There are several lines of evidence linking MMP-9 to FXS. This syndrome is well modeled in mice by the knockout (KO) of the FMRP encoding gene (Fmr1). In fact, the first link between FXS and MMP-9 was revealed by Bilousova et al., who reported increased MMP-9 activity in cultured neurons from Fmr1 KO mice and, furthermore, the disease phenotype of elongated dendritic spines could be rescued by minocycline inhibiting MMP-9 activity. Similarly, another group also showed that inhibiting MMP-9 could rescue the abnormal spine dynamics noted in Fmr1 KO mice. Most interestingly, genetic removal of MMP-9 rescued the ASD-like symptoms of Fragile X in Fmr1 KO mice. In another study, where abnormally high level of MMP-9 was observed in the auditory cortex of Fmr1 KO mice, genetic deletion of MMP-9 was able to rescue habituation deficits.

Furthermore, pharmacological inhibition of elF4E dependent MMP-9 translation (see above) has been able to reverse symptoms of Fragile X in Fmr1 KO mice. In addition, the drug minocycline was able to lower MMP-9 levels in Fmr1 knockout mice, reduced anxiety and rescued Fragile X such as phenotype. Interestingly, metformin, a drug used for treating diabetes, has been shown to normalize elF4E phosphorylation and MMP-9 gene expression, and subsequently rescue the core phenotypes of Fmr1 hemizygous mice.

Perineuronal nets (PNN) are assemblies of the extracellular matrix, which cover the interneurons expressing parvalbumin. Abnormalities in PNN have been reported in schizophrenia and Alzheimer’s disease. MMP-9 is considered as a PNN regulator and thus alterations in its levels might result in PNN abnormalities. In fact, genetic reduction of MMP-9 levels to wild-type equivalence in Fmr1 KO mice led to the restoration of PNN formation around parvalbumin cells in the auditory cortex and rescued altered sound-driven response phenotype in these mice.

ASD-like-phenotype had also been reported in zinc transporter 3 (ZnT3) KO mice along with increased MMP-9 and BDNF levels—possibly due to perturbed zinc homeostasis. Treatment of these mice with minocycline rescued ASD-like-phenotype and reduced BDNF levels.

Notably, it has been suggested that MMP-9 might serve as a very promising target for drugs to treat ASD and FXS patients.

MMPs in schizophrenia and bipolar disorder

Schizophrenia is a neuropsychiatric disorder affecting 0.5% of the human population. The disease is characterized by heterogeneous display of positive symptoms (hallucinations, delusions, and thought disorder), negative symptoms (avolition, restricted affect, poverty of speech, and social withdrawal), and cognitive dysfunction (working memory deficits, executive function, and attentional dysfunction). Schizophrenia onset occurs typically in early adulthood and is usually associated with a lifetime disability. Bipolar disorder (BD) is a major mental disorder with a high risk of suicide. BD onset occurs in adolescence. The disorder is characterized by mania episodes followed by depressive ones. Of note, even though bipolar disorder and schizophrenia are typically considered to be separate diseases entities, in some cases it is difficult to provide a clear separation and these two conditions may be considered as a schizoaffective disorder.

Human data

MMP9 C1562T gene promoter polymorphism has been shown to associate with schizophrenia. An interesting example of gene-schizophrenia association is rs20544 C/T SNP that has been demonstrated to be strongly linked to the disease delusional symptoms. This polymorphism is located within MMP9 3′UTR mRNA and the authors have also shown that it affects RNA structure and binding to FMRP as well as synaptic MMP-9 availability and morphology of dendritic spines. The polymorphism linked to lower MMP-9 synaptic release has been associated with more severe delusional symptoms. Recently, Gregor et al. have shown that the effects of anti-psychotic treatment, as well as the severity of childhood trauma are highly dependent on the type of MMP-9 gene variations. Thus, the SNP rs13925 was found to result in a reduced risk of developing treatment refractory schizophrenia, particularly in the presence of homozygous recessive genotype.

As far as MMP3 is concerned its −1171 5A/6A (rs3025058) polymorphism has been associated with schizophrenia. In this study in Turkish population, it was found that the 6A/6A and 6A allele frequency was less in patients with schizophrenia, whereas the 5A/5A and 5A allele frequency was more.

Measuring the transcript and protein levels of MMPs in schizophrenia has also yielded interesting results. Ali et al. reported that in spite of not finding any correlation between MMP9 −1562C>T SNP and schizophrenia, the levels of MMP-9 were found to be upregulated in serum of schizophrenic patients. An unbiased approach in screening altered levels of plasma proteins in patients with schizophrenia also revealed increased levels of MMP-9 and TIMP-1. Rahimi et al. showed that there were no significant differences in the individual levels of MMP-9 and TIMP-1 genes in schizophrenia patients, but the MMP-9/TIMP-1 ratio was significantly altered (see also Ref.). Similarly, upregulated MMP-9 serum levels were found to be strongly associated with levels of mature BDNF (MMP-9 aids in the formation of mature BDNF from pro-BDNF) in schizophrenia patients. Another independent study confirmed increased MMP-9 activity in the blood of schizophrenia patients. Increased MMP-9 serum levels were likewise found to be correlated to oxidative stress in schizophrenia cases. Similarly, MMP-9 gene expression in blood mononuclear cells was found to be upregulated in schizophrenia patients who did not undergo treatment. Interestingly, the levels were no longer significantly different after the administration of the treatment.

As in schizophrenia, polymorphisms and changes in the levels of MMPs have been associated with BD. Rybakowski et al. originally demonstrated that C1562T MMP9 polymorphism linked to BD. It was also found that the serum levels of MMP-9 were upregulated in patients with BD both during the acute phase and remission of depression. Sodersten et al. observed no differences in the level of MMP-9 in patients with BD but found that its levels correlated positively and significantly with mature BDNF levels, what shall be considered in a context of findings suggesting that MMP-9 may cleave pro-BDNF to its mature form.

As far as MMP10 is concerned, individuals suffering from BD with T/T allele of MMP10 rs486055 (C/T R53K) polymorphism, were reported to have more depressive events than with C/T or C/C alleles. Interestingly MMP-7 levels were also shown to be elevated in patients with BD.

Animal experiments

Clearly, the cognitive symptoms of schizophrenia appear the easiest to model in animals by studying learning and memory phenomena, which, however, might lead to great oversimplifications. Nevertheless, in this context, it is worthy to recall the aforementioned data linking MMP-9 levels to learning and memory functions (see above). In addition, negative symptoms of the disease are apparently relatively easy to model, however, to dissect those from depressive behaviors might be difficult. The positive symptoms of schizophrenia can be modelled by enhanced hyperlocomotor response to such NMDA receptors antagonists as MK-801. Lepeta et al. demonstrated that MMP-9 heterozygous mice display such enhanced hyperlocomotor response to MK-801, thus, this result was in line with the aforementioned clinical data on MMP-9 3′UTR mRNA polymorphism causing lower synaptic MMP-9 levels and linked to enhanced delusional symptoms of the disease.

MMPs in addiction: alcohol, cocaine, methamphetamine, nicotine

Addiction is a condition characterized by compulsive drug use, seeking and other related behaviors, despite knowledge of the negative consequences. Even though in many cases substance use is the most common type of addiction, a person is capable of developing an addiction also to other rewarding behaviors, such as gambling, game playing or internet as well. Exposure to addictive substances has been shown to create long-lasting alterations in brain function. These take place in brain areas and in neuronal circuits involved in appetitive reward learning and memory formation. The overlap between molecular processes involved in the former and pharmacological actions of drugs suggest that the key proteins driving learning and memory are also important players in the formation of addiction.

The role of MMPs in addiction has recently been reviewed. One of the best described MMPs in the context of addiction is MMP-9. Data from human studies indicate that its levels are increased in the hippocampus of cocaine, heroin and alcohol abusers. Furthermore, MMP-9 mRNA level is increased in methamphetamine addicts. Moreover, in alcohol abusers, polymorphism of the MMP-9 gene producing higher protein expression is more frequent in alcoholics’ families than in control subjects’ families. Animal studies revealed the involvement of MMPs in addiction to morphine, methamphetamine, nicotine, ethanol, cocaine and heroin.

MMPs are activated and play functional roles in such particular aspects of addiction, as motivation in mice and human subjects, rewarding effect or relapse/reinstatement in rats. Animals devoid of MMP-9 drink as much alcohol as wild-type animals, yet they are impaired in alcohol seeking when access to ethanol is limited (withdrawal) or requires additional effort to obtain it (motivation). Similar alterations were also observed in MMP-2 and MMP-9 deficient mice, which subjected to methamphetamine treatment did not develop sensitization towards this drug.

Some reports indicate that metalloproteinase inhibitors can reduce behavioral correlates of addiction. MMP-2 and MMP-9 inhibitors reduced sensitization and blocked in mice methamphetamine conditioned place preference (CPP), i.e. rewarding effect of drug manifested by time spent in drug-associated chamber. When infused prior to cocaine administration, a broad spectrum MMP inhibitor blocked acquisition of CPP and reduced its reinstatement after a cocaine-priming injection in rats that underwent CPP extinction. The same inhibitor, when injected intracerebroventricularly to rats exposed to long-term alcohol vapor self-administration prevented the escalation of alcohol vapor intake during acute withdrawal. Similarly, in heroin addiction, MMP inhibition attenuates heroin cue-induced seeking. Not surprisingly then, restoring the availability of MMPs reverses these effects, as overexpressing the active form of MMP-9 in the amygdala increased mice motivation towards ethanol self-administration.

As far as the structural and functional plasticity is concerned, Smith et al. discovered that extinction and reinstatement of cocaine self-administration causes an increase in spine density, together with the enlargement of spine heads in neurons of the nucleus accumbens, a structure particularly involved in execution of motivated behaviors and addiction. This morphological remodeling is associated with MMP-2 and MMP-9 activities and causes strengthening of glutamatergic synapses, measured by the increase in AMPA/NMDA receptors currents ratio. Our studies in the central amygdala, on the other hand, show that high motivation to ethanol self-administration is associated with the enlargement of long and mushroom spines. This effect is not observed in MMP-9 KO mice. Moreover, ethanol consumption and subsequent withdrawal change synaptic efficacy by the formation of silent synapses and the reduction of AMPA/NMDA receptors currents ratio. Silent synapses are immature synaptic connections, which appearance signifies enhanced plasticity. They are strongly involved in cocaine and morphine addiction. Our observations that MMP-9 activity causes an increase in silent synapse number, while genetic ablation of MMP-9 prevents their formation, indicate that the function of this gelatinase is particularly significant in the remodeling of synaptic efficacy.

Concluding remarks

Whereas traditionally, MMPs in the brain used to be considered as enzymes chiefly contributing to a pathological neuronal cell loss occurring in such disorders as various forms of neurodegeneration, stroke, traumatic brain injury, multiple sclerosis, gliomas, etc., the present review offers another look at the brain MMPs. It has been well documented that these enzymes, with MMP-9 serving as a most prominent example (maybe merely because of being the most extensively studied), contribute to learning and memory, as well as such major neuropsychiatric conditions as epilepsy (its development, i.e., epileptogenesis, in particular), schizophrenia, autism spectrum (with particularly strong example of fragile X syndrome), and addiction to various substances of abuse (including alcohol, cocaine, and others), depression, etc. Physiological and pathological synaptic plasticity emerges as a common theme, as far as the mechanisms of all those conditions are concerned. Indeed, the evidence for pivotal role of some MMPs, again MMP-9 in particular, in functional and morphological, physiological and aberrant plasticity of excitatory synapses appears very convincing. The fact that MMP-9 might be locally produced and released at/around those synapses provides further support for this notion. On the other hand, MMPs might be also produced and released by glia and brain-invading leukocytes, fueling a neuroinflammation. To dissect those various activities (including mutual interactions, e.g., during the activation—cleaving off the propeptide—step) of MMPs, their specific expression patterns (cellular origins and time-courses) poses the major research challenge. Addressing this challenge shall advance not only our understanding of the brain in health and disease but may be expected to lead to novel, important disease biomarkers and diagnoses and even new therapies aiming at either inhibiting the enzymes or augmenting their activities. One should not overlook in this context the apparent regulatory and signaling functions of MMPs, their enzymatic nature (particularly amenable for manipulation) and finally, extracellular locus operandi. It has to be finally noted that overlapping substrate specificity of various MMPs poses a great challenge by itself, as far as the development of specific enzyme inhibitors is concerned.

References 267

  1. 1.

    Dityatev A, Rusakov DA. Molecular signals of plasticity at the tetrapartite synapse. Curr Opin Neurobiol. 2011;21(2):353-359.

    Not in our library10.1016/j.conb.2010.12.006 (opens in a new tab)

  2. 2.
    Shaping Synapses by the Neural Extracellular Matrix · 2018
    No notice
  3. 3.

    Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci. 2010;30(46):15337-15357.

    Not in our library10.1523/jneurosci.3467-10.2010 (opens in a new tab)

  4. 4.

    Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 2016;139(Suppl 2):91-114.

    Not in our library10.1111/jnc.13415 (opens in a new tab)

  5. 5.

    Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.

    Not in our library10.1146/annurev.cellbio.17.1.463 (opens in a new tab)

  6. 6.

    Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science. 2002;297(5584):1186-1190.

    Not in our library10.1126/science.1073634 (opens in a new tab)

  7. 7.

    Gossas T, Danielson UH. Characterization of Ca2+ interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation. Biochem J. 2006;398(3):393-398.

    Not in our library10.1042/bj20051933 (opens in a new tab)

  8. 8.

    Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol. 2012;303(8):H919-H930.

    Not in our library10.1152/ajpheart.00577.2012 (opens in a new tab)

  9. 9.

    Kaczmarek L, Lapinska-Dzwonek J, Szymczak S. Matrix metalloproteinases in the adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? EMBO J. 2002;21(24):6643-6648.

    Not in our library10.1093/emboj/cdf676 (opens in a new tab)

  10. 10.

    Kuzniewska B, Rejmak E, Malik AR, Jaworski J, Kaczmarek L, Kalita K. Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol. 2013;33(11):2149-2162.

    Not in our library10.1128/mcb.00008-13 (opens in a new tab)

  11. 11.

    Dziembowska M, Milek J, Janusz A, Rejmak E, Romanowska E, Gorkiewicz T, Tiron A, Bramham CR, Kaczmarek L. Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci. 2012;32(42):14538-14547.

    Not in our library10.1523/jneurosci.6028-11.2012 (opens in a new tab)

  12. 12.

    Jasińska M, Miłek J, Cymerman IA, Łęski S, Kaczmarek L, Dziembowska M. miR-132 regulates dendritic spine structure by direct targeting of matrix metalloproteinase 9 mRNA. Mol Neurobiol. 2016;53(7):4701-4712.

    Not in our library10.1007/s12035-015-9383-z (opens in a new tab)

  13. 13.

    Zybura-Broda K, Wolder-Gontarek M, Ambrozek-Latecka M, Choros A, Bogusz A, Wilemska-Dziaduszycka J, Rylski M. HuR (Elavl1) and HuB (Elavl2) stabilize matrix metalloproteinase-9 mRNA during seizure-induced Mmp-9 expression in neurons. Front Neurosci. 2018;12:224.

    Not in our library10.3389/fnins.2018.00224 (opens in a new tab)

  14. 14.

    Sbai O, Ferhat L, Bernard A, Gueye Y, Ould-Yahoui A, Thiolloy S, Charrat E, Charton G, Tremblay E, Risso JJ, Chauvin JP, Arsanto JP, Rivera S, Khrestchatisky M. Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Mol Cell Neurosci. 2008;39(4):549-568.

    Not in our library10.1016/j.mcn.2008.08.004 (opens in a new tab)

  15. 15.

    Sbai O, Ould-Yahoui A, Ferhat L, Gueye Y, Bernard A, Charrat E, Mehanna A, Risso JJ, Chauvin JP, Fenouillet E, Rivera S, Khrestchatisky M. Differential vesicular distribution and trafficking of MMP-2, MMP-9, and their inhibitors in astrocytes. Glia. 2010;58(3):344-366.

    Not in our library10.1002/glia.20927 (opens in a new tab)

  16. 16.

    Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M, Schneider SW. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res. 2004;64(24):8924-8931.

    Not in our library10.1158/0008-5472.can-04-0324 (opens in a new tab)

  17. 17.

    Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, Cardiff RD. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol. 1998;176(1):206-215.

    Not in our library10.1002/(sici)1097-4652(199807)176:1<206::aid-jcp22>3.0.co;2-3 (opens in a new tab)

  18. 18.
    CD44: molecular interactions, signaling and functions in the nervous system · 2015
    No notice
  19. 19.

    Wang XQ, Sun P, Paller AS. Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin. J Biol Chem. 2003;278(28):25591-25599.

    Not in our library10.1074/jbc.m302211200 (opens in a new tab)

  20. 20.

    Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol. 1999;94(1–2):1-14.

    Not in our library10.1016/s0165-5728(98)00241-0 (opens in a new tab)

  21. 21.

    Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375(6528):244-247.

    Not in our library10.1038/375244a0 (opens in a new tab)

  22. 22.

    Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem. 1997;272(47):29975-29983.

    Not in our library10.1074/jbc.272.47.29975 (opens in a new tab)

  23. 23.

    Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997;389(6646):77-81.

    Not in our library10.1038/37995 (opens in a new tab)

  24. 24.

    Bjorklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem. 2004;279(28):29589-29597.

    Not in our library10.1074/jbc.m401601200 (opens in a new tab)

  25. 25.

    Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA. 2006;103(17):6735-6740.

    Not in our library10.1073/pnas.0510645103 (opens in a new tab)

  26. 26.

    Roderfeld M, Graf J, Giese B, Salguero-Palacios R, Tschuschner A, Muller-Newen G, Roeb E. Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem. 2007;388(11):1227-1234.

    Not in our library10.1515/bc.2007.123 (opens in a new tab)

  27. 27.

    Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 1995;270(31):18506-18511.

    Not in our library10.1074/jbc.270.31.18506 (opens in a new tab)

  28. 28.

    Mantuano E, Inoue G, Li X, Takahashi K, Gaultier A, Gonias SL, Campana WM. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci. 2008;28(45):11571-11582.

    Not in our library10.1523/jneurosci.3053-08.2008 (opens in a new tab)

  29. 29.

    Magnowska M, Gorkiewicz T, Suska A, Wawrzyniak M, Rutkowska-Wlodarczyk I, Kaczmarek L, Wlodarczyk J. Transient ECM protease activity promotes synaptic plasticity. Sci Rep. 2016.

    Not in our library10.1038/srep27757 (opens in a new tab)

  30. 30.

    Murphy N, Lynch MA. Activation of the P2X(7) receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1. J Neurochem. 2012;123(5):761-770.

    Not in our library10.1111/jnc.12031 (opens in a new tab)

  31. 31.
    Activity-Dependent Exocytosis of Lysosomes Regulates the Structural Plasticity of Dendritic Spines · 2017
    No notice
  32. 32.

    Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270(10):5331-5338.

    Not in our library10.1074/jbc.270.10.5331 (opens in a new tab)

  33. 33.

    Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem. 2001;276(5):3203-3214.

    Not in our library10.1074/jbc.m008157200 (opens in a new tab)

  34. 34.

    Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. 2014;71(4):659-672.

    Not in our library10.1007/s00018-013-1457-3 (opens in a new tab)

  35. 35.

    Thevenard J, Verzeaux L, Devy J, Etique N, Jeanne A, Schneider C, Hachet C, Ferracci G, David M, Martiny L, Charpentier E, Khrestchatisky M, Rivera S, Dedieu S, Emonard H. Low-density lipoprotein receptor-related protein-1 mediates endocytic clearance of tissue inhibitor of metalloproteinases-1 and promotes its cytokine-like activities. PLoS One. 2014;9(7):e103839.

    Not in our library10.1371/journal.pone.0103839 (opens in a new tab)

  36. 36.

    Verzeaux L, Belloy N, Thevenard-Devy J, Devy J, Ferracci G, Martiny L, Dedieu S, Dauchez M, Emonard H, Etique N, Devarenne-Charpentier E. Intrinsic dynamics study identifies two amino acids of TIMP-1 critical for its LRP-1-mediated endocytosis in neurons. Sci Rep. 2017;7(1):5375.

    Not in our library10.1038/s41598-017-05039-z (opens in a new tab)

  37. 37.

    Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol. 1998;152(3):729-741.

    Not in our library

  38. 38.

    Sharma NR, Wang X, Majerciak V, Ajiro M, Kruhlak M, Meyers C, Zheng ZM. Cell type- and tissue context-dependent nuclear distribution of human Ago2. J Biol Chem. 2016;291(5):2302-2309.

    Not in our library10.1074/jbc.c115.695049 (opens in a new tab)

  39. 39.

    Ierusalimsky VN, Balaban PM. Type 1 metalloproteinase is selectively expressed in adult rat brain and can be rapidly up-regulated by kainate. Acta Histochem. 2013;115(8):816-826.

    Not in our library10.1016/j.acthis.2013.04.001 (opens in a new tab)

  40. 40.

    Lenglet S, Montecucco F, Mach F, Schaller K, Gasche Y, Copin JC. Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke. Thromb Haemost. 2014;112(2):363-378.

    Not in our library10.1160/th14-01-0007 (opens in a new tab)

  41. 41.

    Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer’s disease. Neurosci Lett. 2000;291(3):201-203.

    Not in our library10.1016/s0304-3940(00)01418-x (opens in a new tab)

  42. 42.

    Allen M, Ghosh S, Ahern GP, Villapol S, Maguire-Zeiss KA, Conant K. Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep. 2016;6:35497.

    Not in our library10.1038/srep35497 (opens in a new tab)

  43. 43.

    Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J, Conant K. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol. 2000;163(2):324-330.

    Not in our library10.1006/exnr.2000.7388 (opens in a new tab)

  44. 44.

    Valente MM, Allen M, Bortolotto V, Lim ST, Conant K, Grilli M. The MMP-1/PAR-1 axis enhances proliferation and neuronal differentiation of adult hippocampal neural progenitor cells. Neural Plast. 2015;2015:646595.

    Not in our library10.1155/2015/646595 (opens in a new tab)

  45. 45.

    Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013;121(3):431-439.

    Not in our library10.1182/blood-2012-09-355958 (opens in a new tab)

  46. 46.

    Dzwonek J, Rylski M, Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett. 2004;567(1):129-135.

    Not in our library10.1016/j.febslet.2004.03.070 (opens in a new tab)

  47. 47.

    Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci. 2002;22(3):920-930.

    Not in our library10.1523/jneurosci.22-03-00920.2002 (opens in a new tab)

  48. 48.

    Aujla PK, Huntley GW. Early postnatal expression and localization of matrix metalloproteinases-2 and -9 during establishment of rat hippocampal synaptic circuitry. J Comp Neurol. 2014;522(6):1249-1263.

    Not in our library10.1002/cne.23468 (opens in a new tab)

  49. 49.

    Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis. 2001;8(5):834-846.

    Not in our library10.1006/nbdi.2001.0435 (opens in a new tab)

  50. 50.

    Smith AC, Kupchik YM, Scofield MD, Gipson CD, Wiggins A, Thomas CA, Kalivas PW. Synaptic plasticity mediating cocaine relapse requires matrix metalloproteinases. Nat Neurosci. 2014;17(12):1655-1657.

    Not in our library10.1038/nn.3846 (opens in a new tab)

  51. 51.

    Vaillant C, Didier-Bazes M, Hutter A, Belin MF, Thomasset N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci. 1999;19(12):4994-5004.

    Not in our library10.1523/jneurosci.19-12-04994.1999 (opens in a new tab)

  52. 52.

    Bednarek N, Clement Y, Lelievre V, Olivier P, Loron G, Garnotel R, Gressens P. Ontogeny of MMPs and TIMPs in the murine neocortex. Pediatr Res. 2009;65(3):296-300.

    Not in our library10.1203/pdr.0b013e3181973aee (opens in a new tab)

  53. 53.

    Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res. 2002;100(1–2):103-117.

    Not in our library10.1016/s0169-328x(02)00132-8 (opens in a new tab)

  54. 54.

    Ogier C, Bernard A, Chollet AM, Le Diguardher T, Hanessian S, Charton G, Khrestchatisky M, Rivera S. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia. 2006;54(4):272-284.

    Not in our library10.1002/glia.20349 (opens in a new tab)

  55. 55.

    Van Hove I, Lemmens K, Van de Velde S, Verslegers M, Moons L. Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. J Neurochem. 2012;123(2):203-216.

    Not in our library10.1111/j.1471-4159.2012.07900.x (opens in a new tab)

  56. 56.

    Del Bigio MR, Jacque CM. Localization of proteinase expression in the developing rabbit brain. Brain Res Dev Brain Res. 1995;86(1–2):345-347.

    Not in our library10.1016/0165-3806(95)00023-7 (opens in a new tab)

  57. 57.

    Wiera G, Nowak D, van Hove I, Dziegiel P, Moons L, Mozrzymas JW. Mechanisms of NMDA receptor- and voltage-gated L-type calcium channel-dependent hippocampal LTP critically rely on proteolysis that is mediated by distinct metalloproteinases. J Neurosci. 2017;37(5):1240-1256.

    Not in our library10.1523/jneurosci.2170-16.2016 (opens in a new tab)

  58. 58.

    Van Hove I, Verslegers M, Buyens T, Delorme N, Lemmens K, Stroobants S, Gantois I, D’Hooge R, Moons L. An aberrant cerebellar development in mice lacking matrix metalloproteinase-3. Mol Neurobiol. 2012;45(1):17-29.

    Not in our library10.1007/s12035-011-8215-z (opens in a new tab)

  59. 59.

    Ulrich R, Gerhauser I, Seeliger F, Baumgartner W, Alldinger S. Matrix metalloproteinases and their inhibitors in the developing mouse brain and spinal cord: a reverse transcription quantitative polymerase chain reaction study. Dev Neurosci. 2005;27(6):408-418.

    Not in our library10.1159/000088455 (opens in a new tab)

  60. 60.

    Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, Zornes PA, Wright JW, Harding JW. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem. 2006;96(5):1227-1241.

    Not in our library10.1111/j.1471-4159.2005.03565.x (opens in a new tab)

  61. 61.

    Wright JW, Meighan SE, Murphy ES, Holtfreter KL, Davis CJ, Olson ML, Benoist CC, Muhunthan K, Harding JW. Habituation of the head-shake response induces changes in brain matrix metalloproteinases-3 (MMP-3) and -9. Behav Brain Res. 2006;174(1):78-85.

    Not in our library10.1016/j.bbr.2006.07.006 (opens in a new tab)

  62. 62.

    Gorter JA, Van Vliet EA, Rauwerda H, Breit T, Stad R, van Schaik L, Vreugdenhil E, Redeker S, Hendriksen E, Aronica E, Lopes da Silva FH, Wadman WJ. Dynamic changes of proteases and protease inhibitors revealed by microarray analysis in CA3 and entorhinal cortex during epileptogenesis in the rat. Epilepsia. 2007;48(Suppl 5):53-64.

    Not in our library10.1111/j.1528-1167.2007.01290.x (opens in a new tab)

  63. 63.

    Woo MS, Park JS, Choi IY, Kim WK, Kim HS. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem. 2008;106(2):770-780.

    Not in our library10.1111/j.1471-4159.2008.05430.x (opens in a new tab)

  64. 64.

    Witek-Zawada B, Koj A. Regulation of expression of stromyelysin-1 by proinflammatory cytokines in mouse brain astrocytes. J Physiol Pharmacol. 2003;54(4):489-496.

    Not in our library

  65. 65.

    Kim YS, Kim SS, Cho JJ, Choi DH, Hwang O, Shin DH, Chun HS, Beal MF, Joh TH. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci. 2005;25(14):3701-3711.

    Not in our library10.1523/jneurosci.4346-04.2005 (opens in a new tab)

  66. 66.

    Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol. 2001;28(1):22-28.

    Not in our library

  67. 67.

    Kim HJ, Fillmore HL, Reeves TM, Phillips LL. Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis. Exp Neurol. 2005;192(1):60-72.

    Not in our library10.1016/j.expneurol.2004.10.014 (opens in a new tab)

  68. 68.

    Skuljec J, Gudi V, Ulrich R, Frichert K, Yildiz O, Pul R, Voss EV, Wissel K, Baumgartner W, Stangel M. Matrix metalloproteinases and their tissue inhibitors in cuprizone-induced demyelination and remyelination of brain white and gray matter. J Neuropathol Exp Neurol. 2011;70(9):758-769.

    Not in our library10.1097/nen.0b013e3182294fad (opens in a new tab)

  69. 69.

    Hughes PM, Wells GM, Perry VH, Brown MC, Miller KM. Comparison of matrix metalloproteinase expression during Wallerian degeneration in the central and peripheral nervous systems. Neuroscience. 2002;113(2):273-287.

    Not in our library10.1016/s0306-4522(02)00183-5 (opens in a new tab)

  70. 70.

    Roberts DJ, Jenne CN, Leger C, Kramer AH, Gallagher CN, Todd S, Parney IF, Doig CJ, Yong VW, Kubes P, Zygun DA. A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans. J Neurotrauma. 2013;30(20):1717-1726.

    Not in our library10.1089/neu.2012.2841 (opens in a new tab)

  71. 71.

    Rome C, Arsaut J, Taris C, Couillaud F, Loiseau H. MMP-7 (matrilysin) expression in human brain tumors. Mol Carcinog. 2007;46(6):446-452.

    Not in our library10.1002/mc.20293 (opens in a new tab)

  72. 72.

    Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol. 1997;23(5):406-415.

    Not in our library10.1111/j.1365-2990.1997.tb01315.x (opens in a new tab)

  73. 73.

    Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van der Valk P, De Groot CJ. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 1997;94(6):590-598.

    Not in our library10.1007/s004010050754 (opens in a new tab)

  74. 74.

    Le AP, Friedman WJ. Matrix metalloproteinase-7 regulates cleavage of pro-nerve growth factor and is neuroprotective following kainic acid-induced seizures. J Neurosci. 2012;32(2):703-712.

    Not in our library10.1523/jneurosci.4128-11.2012 (opens in a new tab)

  75. 75.

    Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, Gearing AJ, Hartung HP. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 1998;121(Pt 1):159-166.

    Not in our library10.1093/brain/121.1.159 (opens in a new tab)

  76. 76.

    Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol. 1999;46(3):391-398.

    Not in our library10.1002/1531-8249(199909)46:3<391::aid-ana15>3.0.co;2-0 (opens in a new tab)

  77. 77.

    Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science. 2001;294(5548):1945-1948.

    Not in our library10.1126/science.1065057 (opens in a new tab)

  78. 78.

    Szklarczyk A, Oyler G, McKay R, Gerfen C, Conant K. Cleavage of neuronal synaptosomal-associated protein of 25 kDa by exogenous matrix metalloproteinase-7. J Neurochem. 2007;102(4):1256-1263.

    Not in our library10.1111/j.1471-4159.2007.04625.x (opens in a new tab)

  79. 79.

    Szklarczyk A, Ewaleifoh O, Beique JC, Wang Y, Knorr D, Haughey N, Malpica T, Mattson MP, Huganir R, Conant K. MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function. FASEB J. 2008;22(11):3757-3767.

    Not in our library10.1096/fj.07-101402 (opens in a new tab)

  80. 80.

    Milward E, Kim KJ, Szklarczyk A, Nguyen T, Melli G, Nayak M, Deshpande D, Fitzsimmons C, Hoke A, Kerr D, Griffin JW, Calabresi PA, Conant K. Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J Neuroimmunol. 2008;193(1–2):140-148.

    Not in our library10.1016/j.jneuroim.2007.11.001 (opens in a new tab)

  81. 81.
    A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders · 2015
    No notice
  82. 82.

    Gawlak M, Gorkiewicz T, Gorlewicz A, Konopacki FA, Kaczmarek L, Wilczynski GM. High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses. Neuroscience. 2009;158(1):167-176.

    Not in our library10.1016/j.neuroscience.2008.05.045 (opens in a new tab)

  83. 83.

    Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, Dziembowska M. The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci. 2013;33(46):18234-18241.

    Not in our library10.1523/jneurosci.2207-13.2013 (opens in a new tab)

  84. 84.

    Szepesi Z, Hosy E, Ruszczycki B, Bijata M, Pyskaty M, Bikbaev A, Heine M, Choquet D, Kaczmarek L, Wlodarczyk J. Synaptically released matrix metalloproteinase activity in control of structural plasticity and the cell surface distribution of GluA1-AMPA receptors. PLoS One. 2014;9(5):e98274.

    Not in our library10.1371/journal.pone.0098274 (opens in a new tab)

  85. 85.

    Langenfurth A, Rinnenthal JL, Vinnakota K, Prinz V, Carlo AS, Stadelmann C, Siffrin V, Peaschke S, Endres M, Heppner F, Glass R, Wolf SA, Kettenmann H. Membrane-type 1 metalloproteinase is upregulated in microglia/brain macrophages in neurodegenerative and neuroinflammatory diseases. J Neurosci Res. 2014;92(3):275-286.

    Not in our library10.1002/jnr.23288 (opens in a new tab)

  86. 86.
    Differential Spatio-Temporal Regulation of MMPs in the 5xFAD Mouse Model of Alzheimer’s disease: Evidence for aPro-Amyloidogenic Role of MT1-MMP · 2014
    Not checked
  87. 87.

    Cazzin C, Mion S, Caldara F, Rimland JM, Domenici E. Microarray analysis of cultured rat hippocampal neurons treated with brain derived neurotrophic factor. Mol Biol Rep. 2011;38(2):983-990.

    Not in our library10.1007/s11033-010-0193-0 (opens in a new tab)

  88. 88.

    De Groef L, Andries L, Lemmens K, Van Hove I, Moons L. Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies. BMC Ophthalmol. 2015;15:187.

    Not in our library10.1186/s12886-015-0176-y (opens in a new tab)

  89. 89.

    Irwin LN, Byers DM. Novel odors affect gene expression for cytokines and proteinases in the rat amygdala and hippocampus. Brain Res. 2012;1489:1-7.

    Not in our library10.1016/j.brainres.2012.10.034 (opens in a new tab)

  90. 90.

    Jaworski DM. Developmental regulation of membrane type-5 matrix metalloproteinase (MT5-MMP) expression in the rat nervous system. Brain Res. 2000;860(1–2):174-177.

    Not in our library10.1016/s0006-8993(00)02035-7 (opens in a new tab)

  91. 91.

    Sekine-Aizawa Y, Hama E, Watanabe K, Tsubuki S, Kanai-Azuma M, Kanai Y, Arai H, Aizawa H, Iwata N, Saido TC. Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain-specific MMP highly expressed in cerebellum. Eur J Neurosci. 2001;13(5):935-948.

    Not in our library10.1046/j.0953-816x.2001.01462.x (opens in a new tab)

  92. 92.

    Hayashita-Kinoh H, Kinoh H, Okada A, Komori K, Itoh Y, Chiba T, Kajita M, Yana I, Seiki M. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ. 2001;12(11):573-580.

    Not in our library

  93. 93.

    Sala C, Segal M. Dendritic spines: the locus of structural and functional plasticity. Physiol Rev. 2014;94(1):141-188.

    Not in our library10.1152/physrev.00012.2013 (opens in a new tab)

  94. 94.

    Lee H, Lee EJ, Song YS, Kim E. Long-term depression-inducing stimuli promote cleavage of the synaptic adhesion molecule NGL-3 through NMDA receptors, matrix metalloproteinases and presenilin/gamma-secretase. Philos Trans R Soc Lond B Biol Sci. 2014;369(1633):20130158.

    Not in our library10.1098/rstb.2013.0158 (opens in a new tab)

  95. 95.

    Meighan PC, Meighan SE, Davis CJ, Wright JW, Harding JW. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. J Neurochem. 2007;102(6):2085-2096.

    Not in our library10.1111/j.1471-4159.2007.04682.x (opens in a new tab)

  96. 96.

    Wojtowicz T, Mozrzymas JW. Late phase of long-term potentiation in the mossy fiber-CA3 hippocampal pathway is critically dependent on metalloproteinases activity. Hippocampus. 2010;20(8):917-921.

    Not in our library10.1002/hipo.20787 (opens in a new tab)

  97. 97.

    Kaliszewska A, Bijata M, Kaczmarek L, Kossut M. Experience-dependent plasticity of the barrel cortex in mice observed with 2-DG brain mapping and c-Fos: effects of MMP-9 KO. Cereb Cortex. 2012;22(9):2160-2170.

    Not in our library10.1093/cercor/bhr303 (opens in a new tab)

  98. 98.

    Pielecka-Fortuna J, Kalogeraki E, Fortuna MG, Lowel S. Optimal level activity of matrix metalloproteinases is critical for adult visual plasticity in the healthy and stroke-affected brain. Elife. 2015;5:e11290.

    Not in our library10.7554/elife.11290 (opens in a new tab)

  99. 99.

    Spolidoro M, Putignano E, Munafo C, Maffei L, Pizzorusso T. Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats. Cereb Cortex. 2012;22(3):725-734.

    Not in our library10.1093/cercor/bhr158 (opens in a new tab)

  100. 100.

    Dityatev A, Schachner M, Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat Rev Neurosci. 2010;11(11):735-746.

    Not in our library10.1038/nrn2898 (opens in a new tab)

  101. 101.

    Huntley GW. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci. 2012;13(11):743-757.

    Not in our library10.1038/nrn3320 (opens in a new tab)

  102. 102.

    Michaluk P, Kaczmarek L. Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ. 2007;14(7):1255-1258.

    Not in our library10.1038/sj.cdd.4402141 (opens in a new tab)

  103. 103.

    Tsilibary E, Tzinia A, Radenovic L, Stamenkovic V, Lebitko T, Mucha M, Pawlak R, Frischknecht R, Kaczmarek L. Neural ECM proteases in learning and synaptic plasticity. Prog Brain Res. 2014;214:135-157.

    Not in our library10.1016/b978-0-444-63486-3.00006-2 (opens in a new tab)

  104. 104.

    Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, Gorecki DC, Ottersen OP, Kaczmarek L. Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem. 2007;282(22):16036-16041.

    Not in our library10.1074/jbc.m700641200 (opens in a new tab)

  105. 105.

    Peixoto RT, Kunz PA, Kwon H, Mabb AM, Sabatini BL, Philpot BD, Ehlers MD. Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuron. 2012;76(2):396-409.

    Not in our library10.1016/j.neuron.2012.07.006 (opens in a new tab)

  106. 106.
    Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations · 2014
    No notice
  107. 107.

    Conant K, Lonskaya I, Szklarczyk A, Krall C, Steiner J, Maguire-Zeiss K, Lim ST. Methamphetamine-associated cleavage of the synaptic adhesion molecule intercellular adhesion molecule-5. J Neurochem. 2011;118(4):521-532.

    Not in our library10.1111/j.1471-4159.2010.07153.x (opens in a new tab)

  108. 108.

    Kelly EA, Tremblay ME, Gahmberg CG, Tian L, Majewska AK. Subcellular localization of intercellular adhesion molecule-5 (telencephalin) in the visual cortex is not developmentally regulated in the absence of matrix metalloproteinase-9. J Comp Neurol. 2014;522(3):676-688.

    Not in our library10.1002/cne.23440 (opens in a new tab)

  109. 109.

    Bajor M, Michaluk P, Gulyassy P, Kekesi AK, Juhasz G, Kaczmarek L. Synaptic cell adhesion molecule-2 and collapsin response mediator protein-2 are novel members of the matrix metalloproteinase-9 degradome. J Neurochem. 2012;122(4):775-788.

    Not in our library10.1111/j.1471-4159.2012.07829.x (opens in a new tab)

  110. 110.

    Gorkiewicz T, Szczuraszek K, Wyrembek P, Michaluk P, Kaczmarek L, Mozrzymas JW. Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons. Hippocampus. 2010;20(10):1105-1108.

    Not in our library10.1002/hipo.20736 (opens in a new tab)

  111. 111.

    Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci. 2009;29(18):6007-6012.

    Not in our library10.1523/jneurosci.5346-08.2009 (opens in a new tab)

  112. 112.

    Lonskaya I, Partridge J, Lalchandani RR, Chung A, Lee T, Vicini S, Hoe HS, Lim ST, Conant K. Soluble ICAM-5, a product of activity dependent proteolysis, increases mEPSC frequency and dendritic expression of GluA1. PLoS One. 2013;8(7):e69136.

    Not in our library10.1371/journal.pone.0069136 (opens in a new tab)

  113. 113.

    Niedringhaus M, Chen X, Conant K, Dzakpasu R. Synaptic potentiation facilitates memory-like attractor dynamics in cultured in vitro hippocampal networks. PLoS One. 2013;8(3):e57144.

    Not in our library10.1371/journal.pone.0057144 (opens in a new tab)

  114. 114.
    MMPs and soluble ICAM-5 increase neuronal excitability within in vitro networks of hippocampal neurons. · 2012
    Not checked
  115. 115.

    Szepesi Z, Bijata M, Ruszczycki B, Kaczmarek L, Wlodarczyk J. Matrix metalloproteinases regulate the formation of dendritic spine head protrusions during chemically induced long-term potentiation. PLoS One. 2013;8(5):e63314.

    Not in our library10.1371/journal.pone.0063314 (opens in a new tab)

  116. 116.

    Bozdagi O, Nagy V, Kwei KT, Huntley GW. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol. 2007;98(1):334-344.

    Not in our library10.1152/jn.00202.2007 (opens in a new tab)

  117. 117.

    Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci. 2006;26(7):1923-1934.

    Not in our library10.1523/jneurosci.4359-05.2006 (opens in a new tab)

  118. 118.

    Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci USA. 2008;105(49):19520-19525.

    Not in our library10.1073/pnas.0807248105 (opens in a new tab)

  119. 119.

    Wiera G, Wozniak G, Bajor M, Kaczmarek L, Mozrzymas JW. Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity. Hippocampus. 2013;23(6):529-543.

    Not in our library10.1002/hipo.22112 (opens in a new tab)

  120. 120.

    Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, Wilczynski GM, Sanchez-Capelo A, Mallet J, Kaczmarek L. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry. 2007;62(4):359-362.

    Not in our library10.1016/j.biopsych.2006.09.012 (opens in a new tab)

  121. 121.

    Gorkiewicz T, Balcerzyk M, Kaczmarek L, Knapska E. Matrix metalloproteinase 9 (MMP-9) is indispensable for long term potentiation in the central and basal but not in the lateral nucleus of the amygdala. Front Cell Neurosci. 2015;9:73.

    Not in our library10.3389/fncel.2015.00073 (opens in a new tab)

  122. 122.

    Bilousova TV, Rusakov DA, Ethell DW, Ethell IM. Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem. 2006;97(1):44-56.

    Not in our library10.1111/j.1471-4159.2006.03701.x (opens in a new tab)

  123. 123.

    Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K, Medvedev N, Wilczek E, De Roo M, Zuschratter W, Muller D, Wilczynski GM, Mozrzymas JW, Stewart MG, Kaczmarek L, Wlodarczyk J. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci. 2011;124(Pt 19):3369-3380.

    Not in our library10.1242/jcs.090852 (opens in a new tab)

  124. 124.

    Tian L, Stefanidakis M, Ning L, Van Lint P, Nyman-Huttunen H, Libert C, Itohara S, Mishina M, Rauvala H, Gahmberg CG. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol. 2007;178(4):687-700.

    Not in our library10.1083/jcb.200612097 (opens in a new tab)

  125. 125.

    Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci. 1997;17(11):4223-4235.

    Not in our library10.1523/jneurosci.17-11-04223.1997 (opens in a new tab)

  126. 126.

    Knapska E, Lioudyno V, Kiryk A, Mikosz M, Gorkiewicz T, Michaluk P, Gawlak M, Chaturvedi M, Mochol G, Balcerzyk M, Wojcik DK, Wilczynski GM, Kaczmarek L. Reward learning requires activity of matrix metalloproteinase-9 in the central amygdala. J Neurosci. 2013;33(36):14591-14600.

    Not in our library10.1523/jneurosci.5239-12.2013 (opens in a new tab)

  127. 127.

    Brown TE, Wilson AR, Cocking DL, Sorg BA. Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory. Neurobiol Learn Mem. 2009;91(1):66-72.

    Not in our library10.1016/j.nlm.2008.09.003 (opens in a new tab)

  128. 128.

    Wright JW, Brown TE, Harding JW. Inhibition of hippocampal matrix metalloproteinase-3 and -9 disrupts spatial memory. Neural Plast. 2007;2007:73813.

    Not in our library10.1155/2007/73813 (opens in a new tab)

  129. 129.

    Bach DR, Tzovara A, Vunder J. Blocking human fear memory with the matrix metalloproteinase inhibitor doxycycline. Mol Psychiatry. 2017.

    Not in our library10.1038/mp.2017.65 (opens in a new tab)

  130. 130.

    Bobinska K, Szemraj J, Galecki P, Talarowska M. The role of MMP genes in recurrent depressive disorders and cognitive functions. Acta Neuropsychiatr. 2016;28(4):221-231.

    Not in our library10.1017/neu.2015.72 (opens in a new tab)

  131. 131.

    Matsumoto J, Hirano Y, Hashimoto K, Ishima T, Kanahara N, Niitsu T, Shiina A, Hashimoto T, Sato Y, Yokote K, Murano S, Kimura H, Hosoda Y, Shimizu E, Iyo M, Nakazato M. Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders. Psychiatry Clin Neurosci. 2017;71(2):124-134.

    Not in our library10.1111/pcn.12490 (opens in a new tab)

  132. 132.

    Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J. Matrix metalloproteinase-9 gene modulates prefrontal cognition in bipolar men. Psychiatr Genet. 2009;19(2):108-109.

    Not in our library10.1097/ypg.0b013e32832080be (opens in a new tab)

  133. 133.

    Gregory MD, Kippenhan JS, Callicott JH, Rubinstein DY, Mattay VS, Coppola R, Berman KF. Sequence variation associated with SLC12A5 gene expression is linked to brain structure and function in healthy adults. Cereb Cortex. 2019.

    Not in our library10.1093/cercor/bhy344 (opens in a new tab)

  134. 134.

    Olson ML, Meighan PC, Brown TE, Asay AL, Benoist CC, Harding JW, Wright JW. Hippocampal MMP-3 elevation is associated with passive avoidance conditioning. Regul Pept. 2008;146(1–3):19-25.

    Not in our library10.1016/j.regpep.2007.07.004 (opens in a new tab)

  135. 135.

    Wright JW, Meighan PC, Brown TE, Wiediger RV, Sorg BA, Harding JW. Habituation-induced neural plasticity in the hippocampus and prefrontal cortex mediated by MMP-3. Behav Brain Res. 2009;203(1):27-34.

    Not in our library10.1016/j.bbr.2009.04.014 (opens in a new tab)

  136. 136.

    Wiediger RV, Wright JW. Influence of dorsal hippocampal lesions and MMP inhibitors on spontaneous recovery following a habituation/classical conditioning head-shake task. Neurobiol Learn Mem. 2009;92(4):504-511.

    Not in our library10.1016/j.nlm.2009.06.009 (opens in a new tab)

  137. 137.

    Brzdak P, Wojcicka O, Zareba-Koziol M, Minge D, Henneberger C, Wlodarczyk J, Mozrzymas JW, Wojtowicz T. Synaptic potentiation at basal and apical dendrites of hippocampal pyramidal neurons involves activation of a distinct set of extracellular and intracellular molecular cues. Cereb Cortex. 2017.

    Not in our library10.1093/cercor/bhx324 (opens in a new tab)

  138. 138.

    Wojtowicz T, Mozrzymas JW. Matrix metalloprotease activity shapes the magnitude of EPSPs and spike plasticity within the hippocampal CA3 network. Hippocampus. 2014;24(2):135-153.

    Not in our library10.1002/hipo.22205 (opens in a new tab)

  139. 139.

    Pauly T, Ratliff M, Pietrowski E, Neugebauer R, Schlicksupp A, Kirsch J, Kuhse J. Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity. PLoS One. 2008;3(7):e2681.

    Not in our library10.1371/journal.pone.0002681 (opens in a new tab)

  140. 140.

    Aerts J, Nys J, Moons L, Hu TT, Arckens L. Altered neuronal architecture and plasticity in the visual cortex of adult MMP-3-deficient mice. Brain Struct Funct. 2015;220(5):2675-2689.

    Not in our library10.1007/s00429-014-0819-4 (opens in a new tab)

  141. 141.

    Monea S, Jordan BA, Srivastava S, DeSouza S, Ziff EB. Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci. 2006;26(8):2300-2312.

    Not in our library10.1523/jneurosci.3521-05.2006 (opens in a new tab)

  142. 142.

    Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD, Moore S, Daria A, Hampel H, Muller V, Giudici C, Nuscher B, Wenninger-Weinzierl A, Kremmer E, Heneka MT, Thal DR, Giedraitis V, Lannfelt L, Muller U, Livesey FJ, Meissner F, Herms J, Konnerth A, Marie H, Haass C. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526(7573):443-447.

    Not in our library10.1038/nature14864 (opens in a new tab)

  143. 143.

    Warren KM, Reeves TM, Phillips LL. MT5-MMP, ADAM-10, and N-cadherin act in concert to facilitate synapse reorganization after traumatic brain injury. J Neurotrauma. 2012;29(10):1922-1940.

    Not in our library10.1089/neu.2012.2383 (opens in a new tab)

  144. 144.

    Berg AT, Cross JH. Towards a modern classification of the epilepsies? Lancet Neurol. 2010;9(5):459-461.

    Not in our library10.1016/s1474-4422(10)70024-7 (opens in a new tab)

  145. 145.

    Lukasiuk K, Wilczynski GM, Kaczmarek L. Extracellular proteases in epilepsy. Epilepsy Res. 2011;96(3):191-206.

    Not in our library10.1016/j.eplepsyres.2011.08.002 (opens in a new tab)

  146. 146.

    Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49(Suppl 1):8-12.

    Not in our library10.1111/j.1528-1167.2008.01443.x (opens in a new tab)

  147. 147.

    Engel J. Epilepsy: structural or functional? AJNR Am J Neuroradiol. 1996;17(2):243-244.

    Not in our library

  148. 148.

    Mikkonen M, Soininen H, Kalvianen R, Tapiola T, Ylinen A, Vapalahti M, Paljarvi L, Pitkanen A. Remodeling of neuronal circuitries in human temporal lobe epilepsy: increased expression of highly polysialylated neural cell adhesion molecule in the hippocampus and the entorhinal cortex. Ann Neurol. 1998;44(6):923-934.

    Not in our library10.1002/ana.410440611 (opens in a new tab)

  149. 149.

    Sutula T, Cascino G, Cavazos J, Parada I, Ramirez L. Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann Neurol. 1989;26(3):321-330.

    Not in our library10.1002/ana.410260303 (opens in a new tab)

  150. 150.

    Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011;10(2):173-186.

    Not in our library10.1016/s1474-4422(10)70310-0 (opens in a new tab)

  151. 151.

    Bronisz E, Kurkowska-Jastrzebska I. Matrix metalloproteinase 9 in epilepsy: the role of neuroinflammation in seizure development. Mediat Inflamm. 2016;2016:7369020.

    Not in our library10.1155/2016/7369020 (opens in a new tab)

  152. 152.

    Zhang JW, Deb S, Gottschall PE. Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. Eur J Neurosci. 1998;10(11):3358-3368.

    Not in our library10.1046/j.1460-9568.1998.00347.x (opens in a new tab)

  153. 153.

    Zhang JW, Deb S, Gottschall PE. Regional and age-related expression of gelatinases in the brains of young and old rats after treatment with kainic acid. Neurosci Lett. 2000;295(1–2):9-12.

    Not in our library10.1016/s0304-3940(00)01582-2 (opens in a new tab)

  154. 154.

    Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol. 2008;180(5):1021-1035.

    Not in our library10.1083/jcb.200708213 (opens in a new tab)

  155. 155.

    Mizoguchi H, Nakade J, Tachibana M, Ibi D, Someya E, Koike H, Kamei H, Nabeshima T, Itohara S, Takuma K, Sawada M, Sato J, Yamada K. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J Neurosci. 2011;31(36):12963-12971.

    Not in our library10.1523/jneurosci.3118-11.2011 (opens in a new tab)

  156. 156.

    Kim GW, Kim HJ, Cho KJ, Kim HW, Cho YJ, Lee BI. The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol Dis. 2009;36(1):169-180.

    Not in our library10.1016/j.nbd.2009.07.008 (opens in a new tab)

  157. 157.

    Takacs E, Nyilas R, Szepesi Z, Baracskay P, Karlsen B, Rosvold T, Bjorkum AA, Czurko A, Kovacs Z, Kekesi AK, Juhasz G. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem Int. 2010;56(6–7):799-809.

    Not in our library10.1016/j.neuint.2010.03.003 (opens in a new tab)

  158. 158.

    Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia. 2003;44(s10):11-17.

    Not in our library10.1046/j.1528-1157.44.s10.4.x (opens in a new tab)

  159. 159.

    Falo MC, Fillmore HL, Reeves TM, Phillips LL. Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. J Neurosci Res. 2006;84(4):768-781.

    Not in our library10.1002/jnr.20986 (opens in a new tab)

  160. 160.

    Falo MC, Reeves TM, Phillips LL. Agrin expression during synaptogenesis induced by traumatic brain injury. J Neurotrauma. 2008;25(7):769-783.

    Not in our library10.1089/neu.2008.0511 (opens in a new tab)

  161. 161.

    Jia F, Pan YH, Mao Q, Liang YM, Jiang JY. Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. J Neurotrauma. 2010;27(6):1059-1068.

    Not in our library10.1089/neu.2009.1067 (opens in a new tab)

  162. 162.

    Truettner JS, Alonso OF, Dietrich WD. Influence of therapeutic hypothermia on matrix metalloproteinase activity after traumatic brain injury in rats. J Cereb Blood Flow Metab. 2005;25(11):1505-1516.

    Not in our library10.1038/sj.jcbfm.9600150 (opens in a new tab)

  163. 163.

    Hayashi T, Kaneko Y, Yu S, Bae E, Stahl CE, Kawase T, van Loveren H, Sanberg PR, Borlongan CV. Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats. Brain Res. 2009;1280:172-177.

    Not in our library10.1016/j.brainres.2009.05.040 (opens in a new tab)

  164. 164.

    Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci. 2000;20(18):7037-7042.

    Not in our library10.1523/jneurosci.20-18-07037.2000 (opens in a new tab)

  165. 165.

    von Gertten C, Holmin S, Mathiesen T, Nordqvist AC. Increases in matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNA after cerebral contusion and depolarisation. J Neurosci Res. 2003;73(6):803-810.

    Not in our library10.1002/jnr.10729 (opens in a new tab)

  166. 166.

    Mizoguchi H, Yamada K. Roles of matrix metalloproteinases and their targets in epileptogenesis and seizures. Clin Psychopharmacol Neurosci. 2013;11(2):45-52.

    Not in our library10.9758/cpn.2013.11.2.45 (opens in a new tab)

  167. 167.

    Pijet B, Stefaniuk M, Kostrzewska-Ksiezyk A, Tsilibary PE, Tzinia A, Kaczmarek L. Elevation of MMP-9 levels promotes epileptogenesis after traumatic brain injury. Mol Neurobiol. 2018;1:1.

    Not in our library10.1007/s12035-018-1061-5 (opens in a new tab)

  168. 168.

    Hoehna Y, Uckermann O, Luksch H, Stefovska V, Marzahn J, Theil M, Gorkiewicz T, Gawlak M, Wilczynski GM, Kaczmarek L, Ikonomidou C. Matrix metalloproteinase 9 regulates cell death following pilocarpine-induced seizures in the developing brain. Neurobiol Dis. 2012;48(3):339-347.

    Not in our library10.1016/j.nbd.2012.06.023 (opens in a new tab)

  169. 169.

    Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci. 2003;18(6):1507-1517.

    Not in our library10.1046/j.1460-9568.2003.02876.x (opens in a new tab)

  170. 170.

    Yeghiazaryan M, Rutkowska-Wlodarczyk I, Konopka A, Wilczynski GM, Melikyan A, Korkotian E, Kaczmarek L, Figiel I. DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014;9(6):e99789.

    Not in our library10.1371/journal.pone.0099789 (opens in a new tab)

  171. 171.

    Yin P, Yang L, Zhou HY, Sun RP. Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy. Med Hypotheses. 2011;76(2):184-186.

    Not in our library10.1016/j.mehy.2010.09.013 (opens in a new tab)

  172. 172.

    Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood–brain barrier damage and neurological sequelae. Clin Infect Dis. 2000;31(1):80-84.

    Not in our library10.1086/313922 (opens in a new tab)

  173. 173.

    Li YJ, Wang ZH, Zhang B, Zhe X, Wang MJ, Shi ST, Bai J, Lin T, Guo CJ, Zhang SJ, Kong XL, Zuo X, Zhao H. Disruption of the blood–brain barrier after generalized tonic-clonic seizures correlates with cerebrospinal fluid MMP-9 levels. J Neuroinflammation. 2013;10:80.

    Not in our library10.1186/1742-2094-10-80 (opens in a new tab)

  174. 174.

    Romi F, Helgeland G, Gilhus NE. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur Neurol. 2012;67(2):121-128.

    Not in our library10.1159/000334862 (opens in a new tab)

  175. 175.

    Suenaga N, Ichiyama T, Kubota M, Isumi H, Tohyama J, Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci. 2008;266(1–2):126-130.

    Not in our library10.1016/j.jns.2007.09.011 (opens in a new tab)

  176. 176.

    Ichiyama T, Morishima T, Kajimoto M, Matsushige T, Matsubara T, Furukawa S. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J. 2007;26(6):542-544.

    Not in our library10.1097/inf.0b013e31803994a0 (opens in a new tab)

  177. 177.

    Gupta RK, Awasthi R, Garg RK, Kumar N, Gupta PK, Singh AK, Sahoo P, Paliwal VK, Prasad KN, Pandey CM, Rathore RK. T1-weighted dynamic contrast-enhanced MR evaluation of different stages of neurocysticercosis and its relationship with serum MMP-9 expression. AJNR Am J Neuroradiol. 2013;34(5):997-1003.

    Not in our library10.3174/ajnr.a3346 (opens in a new tab)

  178. 178.

    Acar G, Tanriover G, Acar F, Demir R. Increased expression of matrix metalloproteinase-9 in patients with temporal lobe epilepsy. Turk Neurosurg. 2015;25(5):749-756.

    Not in our library10.5137/1019-5149.jtn.10738-14.0 (opens in a new tab)

  179. 179.

    Konopka A, Grajkowska W, Ziemianska K, Roszkowski M, Daszkiewicz P, Rysz A, Marchel A, Koperski L, Wilczynski GM, Dzwonek J. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res. 2013;104(1–2):45-58.

    Not in our library10.1016/j.eplepsyres.2012.09.018 (opens in a new tab)

  180. 180.

    Li S, Yu S, Zhang C, Shu H, Liu S, An N, Yang M, Yin Q, Yang H. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Res. 2012;1453:46-55.

    Not in our library10.1016/j.brainres.2012.03.009 (opens in a new tab)

  181. 181.

    Quirico-Santos T, Nascimento Mello A, Casimiro Gomes A, de Carvalho LP, de Souza JM, Alves-Leon S. Increased metalloprotease activity in the epileptogenic lesion—lobectomy reduces metalloprotease activity and urokinase-type uPAR circulating levels. Brain Res. 2013;1538:172-181.

    Not in our library10.1016/j.brainres.2013.09.044 (opens in a new tab)

  182. 182.

    Zybura-Broda K, Amborska R, Ambrozek-Latecka M, Wilemska J, Bogusz A, Bucko J, Konopka A, Grajkowska W, Roszkowski M, Marchel A, Rysz A, Koperski L, Wilczynski GM, Kaczmarek L, Rylski M. Epigenetics of epileptogenesis-evoked upregulation of matrix metalloproteinase-9 in hippocampus. PLoS One. 2016;11(8):e0159745.

    Not in our library10.1371/journal.pone.0159745 (opens in a new tab)

  183. 183.

    Shahar E, Attias U, Savulescu D, Genizin J, Gavish M, Nagler R. Oxidative stress, metalloproteinase and LDH in children with intractable and non-intractable epilepsy as reflected in salivary analysis. Epilepsy Res. 2014;108(1):117-124.

    Not in our library10.1016/j.eplepsyres.2013.10.003 (opens in a new tab)

  184. 184.

    Ikonomidou C. Matrix metalloproteinases and epileptogenesis. Mol Cell Pediatr. 2014;1(1):6.

    Not in our library10.1186/s40348-014-0006-y (opens in a new tab)

  185. 185.

    Wang R, Zeng GQ, Tong RZ, Zhou D, Hong Z. Serum matrix metalloproteinase-2: a potential biomarker for diagnosis of epilepsy. Epilepsy Res. 2016;122:114-119.

    Not in our library10.1016/j.eplepsyres.2016.02.009 (opens in a new tab)

  186. 186.

    Lee J, Lim E, Kim Y, Li E, Park S. Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J Endocrinol. 2010;205(3):263-270.

    Not in our library10.1677/joe-10-0040 (opens in a new tab)

  187. 187.

    Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J. Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res. 2005;79(4):522-534.

    Not in our library10.1002/jnr.20387 (opens in a new tab)

  188. 188.

    Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery. 2009;65(4):702-708.

    Not in our library10.1227/01.neu.0000351768.11363.48 (opens in a new tab)

  189. 189.

    Gorter JA, van Vliet EA, Aronica E. Status epilepticus, blood–brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav. 2015;49:13-16.

    Not in our library10.1016/j.yebeh.2015.04.047 (opens in a new tab)

  190. 190.

    World Health Organization (2013) Investing in mental health: Evidence for action. WHO Library Cataloguing-in-Publication Data. http://www.who.int/mental_health/publications/financing/investing_in_mh_2013/en/. Accessed 5 June 2019

    Not in our library

  191. 191.

    Stein DJ, Phillips KA, Bolton D, Fulford KW, Sadler JZ, Kendler KS. What is a mental/psychiatric disorder? From DSM-IV to DSM-V. Psychol Med. 2010;40(11):1759-1765.

    Not in our library10.1017/s0033291709992261 (opens in a new tab)

  192. 192.

    Brus MJ, Solanto MV, Goldberg JF. Adult ADHD vs. bipolar disorder in the DSM-5 era: a challenging differentiation for clinicians. J Psychiatr Pract. 2014;20(6):428-437.

    Not in our library10.1097/01.pra.0000456591.20622.9e (opens in a new tab)

  193. 193.

    Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999;105(5):418-423.

    Not in our library10.1007/s004390051124 (opens in a new tab)

  194. 194.

    Bobinska K, Szemraj J, Czarny P, Galecki P. Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder. J Affect Disord. 2016;205:119-129.

    Not in our library10.1016/j.jad.2016.03.068 (opens in a new tab)

  195. 195.

    Lundberg AK, Jonsson S, Stenmark J, Kristenson M, Jonasson L. Stress-induced release of matrix metalloproteinase-9 in patients with coronary artery disease: the possible influence of cortisol. Psychoneuroendocrinology. 2016;73:117-124.

    Not in our library10.1016/j.psyneuen.2016.07.219 (opens in a new tab)

  196. 196.
    Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control Collections · 2010
    No notice
  197. 197.
    Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder · 2012
    Corrected
  198. 198.

    Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population. Psychosom Med. 2009;71(3):292-300.

    Not in our library10.1097/psy.0b013e3181960e7f (opens in a new tab)

  199. 199.

    Shibasaki C, Takebayashi M, Itagaki K, Abe H, Kajitani N, Okada-Tsuchioka M, Yamawaki S. Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. Int J Neuropsychopharmacol. 2016.

    Not in our library10.1093/ijnp/pyw019 (opens in a new tab)

  200. 200.

    Bobinska K, Szemraj J, Czarny P, Galecki P. Expression and activity of metalloproteinases in depression. Med Sci Monit. 2016;22:1334-1341.

    Not in our library10.12659/msm.895978 (opens in a new tab)

  201. 201.

    Aguayo FI, Pacheco AA, Garcia-Rojo GJ, Pizarro-Bauerle JA, Doberti AV, Tejos M, Garcia-Perez MA, Rojas PS, Fiedler JL. Matrix metalloproteinase 9 displays a particular time response to acute stress: variation in its levels and activity distribution in rat hippocampus. ACS Chem Neurosci. 2018;9(5):945-956.

    Not in our library10.1021/acschemneuro.7b00387 (opens in a new tab)

  202. 202.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 2013.

    Not in our library

  203. 203.

    Abbeduto L, McDuffie A, Thurman AJ. The fragile X syndrome-autism comorbidity: what do we really know? Front Genet. 2014;5:355.

    Not in our library10.3389/fgene.2014.00355 (opens in a new tab)

  204. 204.

    Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897-1903.

    Not in our library10.1002/ajmg.a.36023 (opens in a new tab)

  205. 205.

    Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr. 2013;34(3):147-155.

    Not in our library10.1097/dbp.0b013e318287cd17 (opens in a new tab)

  206. 206.
    Open-label add-on treatment trial of minocycline in fragile X syndrome · 2010
    No notice
  207. 207.

    Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 2013;27(10):956-963.

    Not in our library10.1177/0269881113494105 (opens in a new tab)

  208. 208.

    Gkogkas CG, Khoutorsky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, Kaminari A, Fragkouli A, Nader K, Price TJ, Konicek BW, Graff JR, Tzinia AK, Lacaille JC, Sonenberg N. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 2014;9(5):1742-1755.

    Not in our library10.1016/j.celrep.2014.10.064 (opens in a new tab)

  209. 209.

    Abdallah MW, Pearce BD, Larsen N, Greaves-Lord K, Norgaard-Pedersen B, Hougaard DM, Mortensen EL, Grove J. Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study. Autism Res. 2012;5(6):428-433.

    Not in our library10.1002/aur.1254 (opens in a new tab)

  210. 210.
    Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders · 2016
    No notice
  211. 211.

    Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94-102.

    Not in our library10.1136/jmg.2008.061796 (opens in a new tab)

  212. 212.

    Nagaoka A, Takehara H, Hayashi-Takagi A, Noguchi J, Ishii K, Shirai F, Yagishita S, Akagi T, Ichiki T, Kasai H. Abnormal intrinsic dynamics of dendritic spines in a fragile X syndrome mouse model in vivo. Sci Rep. 2016;6:26651.

    Not in our library10.1038/srep26651 (opens in a new tab)

  213. 213.

    Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014;34(30):9867-9879.

    Not in our library10.1523/jneurosci.1162-14.2014 (opens in a new tab)

  214. 214.

    Lovelace JW, Wen TH, Reinhard S, Hsu MS, Sidhu H, Ethell IM, Binder DK, Razak KA. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2016;89:126-135.

    Not in our library10.1016/j.nbd.2016.02.002 (opens in a new tab)

  215. 215.

    Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Res. 2012;1439:7-14.

    Not in our library10.1016/j.brainres.2011.12.041 (opens in a new tab)

  216. 216.

    Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, Sharma V, Pooters T, Nagpal A, Skalecka A, Truong VT, Wiebe S, Groves IA, Jafarnejad SM, Chapat C, McCullagh EA, Gamache K, Nader K, Lacaille JC, Gkogkas CG, Sonenberg N. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. 2017;23(6):674-677.

    Not in our library10.1038/nm.4335 (opens in a new tab)

  217. 217.
    The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders · 2018
    No notice
  218. 218.

    Yoo MH, Kim TY, Yoon YH, Koh JY. Autism phenotypes in ZnT3 null mice: involvement of zinc dyshomeostasis, MMP-9 activation and BDNF upregulation. Sci Rep. 2016;6:28548.

    Not in our library10.1038/srep28548 (opens in a new tab)

  219. 219.

    Castagnola S, Bardoni B, Maurin T. The search for an effective therapy to treat fragile X syndrome: dream or reality? Front Synaptic Neurosci. 2017;9:15.

    Not in our library10.3389/fnsyn.2017.00015 (opens in a new tab)

  220. 220.
    A Systematic Review of the Prevalence of Schizophrenia · 2005
    No notice
  221. 221.

    Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508.

    Not in our library10.1136/bmj.e8508 (opens in a new tab)

  222. 222.

    Beentjes TA, Goossens PJ, Poslawsky IE. Caregiver burden in bipolar hypomania and mania: a systematic review. Perspect Psychiatr Care. 2012;48(4):187-197.

    Not in our library10.1111/j.1744-6163.2012.00328.x (opens in a new tab)

  223. 223.

    Malaspina D, Owen MJ, Heckers S, Tandon R, Bustillo J, Schultz S, Barch DM, Gaebel W, Gur RE, Tsuang M, Van Os J, Carpenter W. Schizoaffective disorder in the DSM-5. Schizophr Res. 2013;150(1):21-25.

    Not in our library10.1016/j.schres.2013.04.026 (opens in a new tab)

  224. 224.

    Rybakowski JK, Skibinska M, Kapelski P, Kaczmarek L, Hauser J. Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophr Res. 2009;109(1–3):90-93.

    Not in our library10.1016/j.schres.2009.02.005 (opens in a new tab)

  225. 225.

    Han H, He X, Tang J, Liu W, Liu K, Zhang J, Wang X, Xu Y, Chen X. The C(-1562)T polymorphism of matrix metalloproteinase-9 gene is associated with schizophrenia in China. Psychiatry Res. 2011;190(1):163-164.

    Not in our library10.1016/j.psychres.2011.04.026 (opens in a new tab)

  226. 226.

    Lepeta K, Purzycka KJ, Pachulska-Wieczorek K, Mitjans M, Begemann M, Vafadari B, Bijata K, Adamiak RW, Ehrenreich H, Dziembowska M, Kaczmarek L. A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Mol Med. 2017;9(8):1100-1116.

    Not in our library10.15252/emmm.201707723 (opens in a new tab)

  227. 227.

    McGregor N, Thompson N, O’Connell KS, Emsley R, van der Merwe L, Warnich L. Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort. Psychiatry Res. 2018;262:141-148.

    Not in our library10.1016/j.psychres.2018.01.044 (opens in a new tab)

  228. 228.

    Kucukali CI, Aydin M, Ozkok E, Bilge E, Orhan N, Zengin A, Kara I. Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):557-561.

    Not in our library10.1016/j.pnpbp.2009.02.012 (opens in a new tab)

  229. 229.

    Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. 2017;188:98-109.

    Not in our library10.1016/j.schres.2017.01.016 (opens in a new tab)

  230. 230.

    Rahimi S, Sayad A, Moslemi E, Ghafouri-Fard S, Taheri M. Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients. Metab Brain Dis. 2017;32(5):1537-1542.

    Not in our library10.1007/s11011-017-0043-z (opens in a new tab)

  231. 231.

    Jeffries CD, Perkins DO, Fournier M, Do KQ, Cuenod M, Khadimallah I, Domenici E, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang M, Walker EF, Woods SW. Networks of blood proteins in the neuroimmunology of schizophrenia. Transl Psychiatry. 2018;8(1):112.

    Not in our library10.1038/s41398-018-0158-y (opens in a new tab)

  232. 232.

    Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett. 2013;556:37-41.

    Not in our library10.1016/j.neulet.2013.09.059 (opens in a new tab)

  233. 233.

    Chang SH, Chiang SY, Chiu CC, Tsai CC, Tsai HH, Huang CY, Hsu TC, Tzang BS. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 2011;187(3):341-346.

    Not in our library10.1016/j.psychres.2010.04.049 (opens in a new tab)

  234. 234.

    Devanarayanan S, Nandeesha H, Kattimani S, Sarkar S. Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study. Clin Chem Lab Med. 2016;54(3):447-452.

    Not in our library10.1515/cclm-2015-0212 (opens in a new tab)

  235. 235.

    Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, Mendis J, Suriyakumara K, Schall U, Tooney PA. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int J Neuropsychopharmacol. 2013;16(7):1483-1503.

    Not in our library10.1017/s1461145713000035 (opens in a new tab)

  236. 236.

    Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J. Matrix metalloproteinase-9 gene and bipolar mood disorder. Neuromol Med. 2009;11(2):128-132.

    Not in our library10.1007/s12017-009-8072-3 (opens in a new tab)

  237. 237.

    Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J Affect Disord. 2013;146(2):286-289.

    Not in our library10.1016/j.jad.2012.07.019 (opens in a new tab)

  238. 238.

    Sodersten K, Palsson E, Ishima T, Funa K, Landen M, Hashimoto K, Agren H. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord. 2014;160:1-9.

    Not in our library10.1016/j.jad.2014.01.009 (opens in a new tab)

  239. 239.

    Drago A, Monti B, De Ronchi D, Serretti A. Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients. Neuropsychobiology. 2014;69(2):76-82.

    Not in our library10.1159/000356971 (opens in a new tab)

  240. 240.

    Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA, Feeder SE, Tye SJ, Choi DS, Biernacka JM. Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry. 2015;5:e689.

    Not in our library10.1038/tp.2015.185 (opens in a new tab)

  241. 241.

    Nassan M, Jia YF, Jenkins G, Colby C, Feeder S, Choi DS, Veldic M, McElroy SL, Bond DJ, Weinshilboum R, Biernacka JM, Frye MA. Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: applications of a proteomic informed genomic approach. J Psychiatr Res. 2017;95:208-212.

    Not in our library10.1016/j.jpsychires.2017.07.005 (opens in a new tab)

  242. 242.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 2000.

    Not in our library

  243. 243.

    Grant JE, Potenza MN, Weinstein A, Gorelick DA. Introduction to behavioral addictions. Am J Drug Alcohol Abuse. 2010;36(5):233-241.

    Not in our library10.3109/00952990.2010.491884 (opens in a new tab)

  244. 244.

    Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712-725.

    Not in our library10.1016/j.cell.2015.07.046 (opens in a new tab)

  245. 245.

    Torregrossa MM, Corlett PR, Taylor JR. Aberrant learning and memory in addiction. Neurobiol Learn Mem. 2011;96(4):609-623.

    Not in our library10.1016/j.nlm.2011.02.014 (opens in a new tab)

  246. 246.

    Smith AC, Scofield MD, Kalivas PW. The tetrapartite synapse: extracellular matrix remodeling contributes to corticoaccumbens plasticity underlying drug addiction. Brain Res. 2015;1628(Pt A):29-39.

    Not in our library10.1016/j.brainres.2015.03.027 (opens in a new tab)

  247. 247.

    Mash DC, ffrench-Mullen J, Adi N, Qin Y, Buck A, Pablo J. Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One. 2007;2(11):e1187.

    Not in our library10.1371/journal.pone.0001187 (opens in a new tab)

  248. 248.

    Kovatsi L, Batzios S, Nikolaou K, Fragou D, Njau S, Tsatsakis A, Karakiulakis G, Papakonstantinou E. Alterations in serum MMP and TIMP concentrations following chronic heroin abuse. Toxicol Mech Methods. 2013;23(5):377-381.

    Not in our library10.3109/15376516.2012.758681 (opens in a new tab)

  249. 249.

    Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari ST. Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Investig. 2002;32(4):225-229.

    Not in our library10.1046/j.1365-2362.2002.00975.x (opens in a new tab)

  250. 250.

    Wang Q, Ishikawa T, Michiue T, Zhu BL, Guan DW, Maeda H. Molecular pathology of brain matrix metalloproteases, claudin5, and aquaporins in forensic autopsy cases with special regard to methamphetamine intoxication. Int J Legal Med. 2014;128(3):469-474.

    Not in our library10.1007/s00414-014-0972-6 (opens in a new tab)

  251. 251.

    Samochowiec A, Grzywacz A, Kaczmarek L, Bienkowski P, Samochowiec J, Mierzejewski P, Preuss UW, Grochans E, Ciechanowicz A. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family and case control study. Brain Res. 2010;1327:103-106.

    Not in our library10.1016/j.brainres.2010.02.072 (opens in a new tab)

  252. 252.

    Nakamoto K, Kawasaki S, Kobori T, Fujita-Hamabe W, Mizoguchi H, Yamada K, Nabeshima T, Tokuyama S. Involvement of matrix metalloproteinase-9 in the development of morphine tolerance. Eur J Pharmacol. 2012;683(1–3):86-92.

    Not in our library10.1016/j.ejphar.2012.03.006 (opens in a new tab)

  253. 253.

    Liu Y, Brown S, Shaikh J, Fishback JA, Matsumoto RR. Relationship between methamphetamine exposure and matrix metalloproteinase 9 expression. NeuroReport. 2008;19(14):1407-1409.

    Not in our library10.1097/wnr.0b013e32830dd606 (opens in a new tab)

  254. 254.

    Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y, Nabeshima T. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J Neurochem. 2007;100(6):1579-1588.

    Not in our library10.1111/j.1471-4159.2006.04288.x (opens in a new tab)

  255. 255.
    A Role for Matrix Metalloproteinases in Nicotine-Induced Conditioned Place Preference and Relapse in Adolescent Female Rats · 2013
    Not checked
  256. 256.

    Smith AW, Nealey KA, Wright JW, Walker BM. Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. Neurobiol Learn Mem. 2011;96(2):199-206.

    Not in our library10.1016/j.nlm.2011.04.011 (opens in a new tab)

  257. 257.

    Stefaniuk M, Beroun A, Lebitko T, Markina O, Leski S, Meyza K, Grzywacz A, Samochowiec J, Samochowiec A, Radwanska K, Kaczmarek L. Matrix metalloproteinase-9 and synaptic plasticity in the central amygdala in control of alcohol-seeking behavior. Biol Psychiatry. 2017;81(11):907-917.

    Not in our library10.1016/j.biopsych.2016.12.026 (opens in a new tab)

  258. 258.

    Wright JW, Masino AJ, Reichert JR, Turner GD, Meighan SE, Meighan PC, Harding JW. Ethanol-induced impairment of spatial memory and brain matrix metalloproteinases. Brain Res. 2003;963(1–2):252-261.

    Not in our library10.1016/s0006-8993(02)04036-2 (opens in a new tab)

  259. 259.

    Brown TE, Forquer MR, Cocking DL, Jansen HT, Harding JW, Sorg BA. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn Mem. 2007;14(3):214-223.

    Not in our library10.1101/lm.476207 (opens in a new tab)

  260. 260.

    Brown TE, Forquer MR, Harding JW, Wright JW, Sorg BA. Increase in matrix metalloproteinase-9 levels in the rat medial prefrontal cortex after cocaine reinstatement of conditioned place preference. Synapse. 2008;62(12):886-889.

    Not in our library10.1002/syn.20562 (opens in a new tab)

  261. 261.

    Mizoguchi H, Yamada K, Mouri A, Niwa M, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y, Nabeshima T. Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J Neurochem. 2007;102(5):1548-1560.

    Not in our library10.1111/j.1471-4159.2007.04623.x (opens in a new tab)

  262. 262.

    Mizoguchi H, Yamada K, Nabeshima T. Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. J Pharmacol Sci. 2008;106(1):9-14.

    Not in our library10.1254/jphs.fm0070139 (opens in a new tab)

  263. 263.

    Van den Oever MC, Lubbers BR, Goriounova NA, Li KW, Van der Schors RC, Loos M, Riga D, Wiskerke J, Binnekade R, Stegeman M, Schoffelmeer AN, Mansvelder HD, Smit AB, De Vries TJ, Spijker S. Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking. Neuropsychopharmacology. 2010;35(10):2120-2133.

    Not in our library10.1038/npp.2010.90 (opens in a new tab)

  264. 264.

    Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry. 2011;16(10):974-986.

    Not in our library10.1038/mp.2011.46 (opens in a new tab)

  265. 265.

    Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature. 1995;375(6530):400-404.

    Not in our library10.1038/375400a0 (opens in a new tab)

  266. 266.

    Huang YH, Lin Y, Mu P, Lee BR, Brown TE, Wayman G, Marie H, Liu W, Yan Z, Sorg BA, Schluter OM, Zukin RS, Dong Y. In vivo cocaine experience generates silent synapses. Neuron. 2009;63(1):40-47.

    Not in our library10.1016/j.neuron.2009.06.007 (opens in a new tab)

  267. 267.

    Graziane NM, Sun S, Wright WJ, Jang D, Liu Z, Huang YH, Nestler EJ, Wang YT, Schlüter OM, Dong Y. Opposing mechanisms mediate morphine- and cocaine-induced generation of silent synapses. Nat Neurosci. 2016;19(7):915-925.

    Not in our library10.1038/nn.4313 (opens in a new tab)

Cited by papers we hold 3

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.